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Abstract  
MicroRNAs (miRNAs) are short (~ 22 nucleotides long) noncoding RNAs that 
regulate gene expression post-transcriptionally. They control the expression of 
various genes that are crucial for cellular function, development and human 
diseases. Tools to regulate the level and function of miRNAs facilitate the studies 
of their functions and have therapeutic applications. In my thesis, I developed a 
new customizable miRNA biogenesis inhibitor to regulate miRNAs.  
Antisense oligonucleotides (ASOs) have been used to regulate miRNA through 
controlling their production or function. Although commonly used due to the fact 
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that they are ease to design, several limitations exist for ASOs including serious 
off target effects, low cellular permeability and poor pharmacokinetics and 
distribution. To address these limitations, we proposed a new class of ASO based 
bi-functional molecules using short ASOs as the pre-miRNA recognition unit linked 
to a RNase III inhibitor as a Dicer inhibitor to block miRNA maturation. We showed 
the feasibility of the bi-functional strategy and optimized the bi-functional molecules 
through enhancing each functional unit as compounds 12, 22 and 25. Additionally, 
we identified cell penetrating peptide (CPP) that facilitate the delivery of bi-
functional molecules to address the cell permeability issue.  
We also explored the feasibility of using cyclic peptidomimetics as an alternative 
class of molecule to target RNAs, which can be used as our pre-miRNA recognition 
unit in the bi-functional regulator. We identified a new pre-miR-155 binder 
(compound 27) that inhibits miR-155 biogenesis. Applying RNAseq and 
bioinformatics analysis, we investigated its targeting selectivity and downstream 
effects.  
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Chapter 1 
Introduction 
1.1 Biogenesis and regulatory mechanism of miRNAs  
Since the first discovery of microRNA (lin4) in 1993 which targets lin-14 gene and 
controls the larval development of C. elegans1, more than 15,000 microRNAs 
(miRNAs or miR) have been discovered.2 Out of these, more than 2500 are 
expressed in human cells and each of these is found to regulate the expression of 
numerous protein-coding genes (tens to hundreds). MiRNAs are ~ 21 to 23 
nucleotide noncoding single-stranded RNAs (ssRNAs) that have important role in 
post transcriptional gene regulation either by mediating transcriptional repression 
or by degrading their target mRNAs. Furthermore, these non-coding RNAs play 
crucial roles in diverse biological activities such as cell proliferation, differentiation, 
metabolism as well as apoptosis3. 
There are two pathways for the processing of miRNA genes transcribed from RNA 
polymerase II promoters, i.e. canonical and non-canonical pathways. In canonical 
pathway, RNA polymerase II transcribes miRNAs as primary miRNA (pri-miRNA) 
hairpins, which are further processed by the Drosha-DGCR8 (DiGeorge syndrome 
critical region 8) complex to precursor miRNAs (pre-miRNAs).4-6 Pre-miRNAs in 
turn transported into the cytoplasm by Exportin 5 and further processed by Dicer-
TRBP (TAR RNA-binding protein 2) and loaded into Argonaute 2 (AGO2) to form 
RNA-induced silencing complexes (RISCs) to suppress downstream gene 
expression. In non-canonical pathway, pre-miRNAs are derived as the 
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spliceosome-dependent mechanisms bypassing Drosha and the formed pre-
miRNAs are processed by Dicer to give mature miRNAs to be loaded into an RNA-
induced silencing complex (RISC) as in the canonical pathway.7,8 RISC loaded  
Figure 1.1: miRNA biogenesis and functions3
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with mature miRNA targets complementary 3’-UTR region of mRNA sequence and 
results in the post transcriptional gene silencing either by mRNA degradation or by 
translational repression or both, first translational repression followed by mRNA 
degradation9-12. (Fig 1.1) 
Primarily miRNAs act as post transcriptional gene regulator by targeting mRNA 
through base pairing, resulting in either mRNA degradation or translation 
repression depending on the extent of complementarity. The mature miRNA strand 
loaded within RISC complex, comprises a seed region of miRNA where nucleotide 
2-8 precisely match the complementary sequence of 3’-UTR the mRNA to be 
targeted. Depending on the extent of base pairing outside the seed region, mRNA 
may either undergo degradation or translational repression. For example, perfect 
complementarity between miRNA and mRNA (mainly in plant cell) results into 
endonuclease mRNA degradation13 whereas imperfect complementarity with 
Figure 1.2: Mechanism of miRNA targeting.13
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some bulges or mismatched regions (mainly in animal cells) results in to 
translational repression or followed by mRNA degradation14-17 (Fig 1.2). 
Imperfect complementarity between miRNAs and targeted mRNAs can have direct 
effects on protein translation by causing the inhibitory action at the various stages 
of translation, e.g. repression at the initiation step by blocking the recruitment of 
40S and /or 60Sribosomes near the 5’-cap of mRNA, ribosomal drop-off from 
mRNA by dissociation 40S/60S ribosomes, by hindering elongation through 
blocking ribosomes from joining during elongation process. Additionally, de-
adenylation of 3’poly-A tail of the mRNA will cause indirect translational repression 
resulting in the enhanced mRNA degradation (Fig 1.3).18-31 
 
Figure 1.3: Post-transcriptional gene regulation by miRNAs13
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1.2 Functions of miRNAs and their links to human diseases  
MiRNAs play important roles in physiological homeostasis and pathophysiological 
conditions in diseases. Some miRNAs are more tissue specific and its expression 
level indicates certain pathological or physiological condition of related organs. 
Many researchers have found involvement of miRNAs in cell and tissue 
development, cancers, cardiovascular system, metabolism, viral infections, 
neuropsychiatric disorders etc. (examples in Table 1.1)3,13, 32-54 
Involved in  Role Examples of miRNAs 
involved 
Cell and Tissue 
Development 
• Proliferation and differentiation of 
embryonic stem (ES) cells. 
• Lineage commitment during 
embryogenesis. 
• Maturation of multiple tissues. 
• miR-290 cluster 
and miR-21 
• miR-133b 
• miR-1, miR-133 
and miR-143 
 
Cancer • Tumorigenesis and Metastasis 
• Oncogene suppressor 
• miR-17-92 
cluster 
(oncomiR-1) and 
miR-10b 
• miR-15a, miR-
16-1, miR-126, 
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miR-355, miR-
200 etc. 
Cardiovascular 
system 
• Endothelial cell (EC) proliferation 
and angiogenesis 
• Cardiac function 
• Oxidative stress regulation 
• Let-7f and miR-
27b 
• miR-1 and miR-
133 
• miR-21, miR-221 
and miR-222 
Metabolism • Tissue differentiation (involved in 
energy production, utilization and 
storage) 
• Regulation of insulin release and 
metabolism 
• Amino acid and lipid metabolism  
• miR-375 and 
miR-29b 
• miR-122, miR-
103 and miR-107 
 
Table 1.1: miRNAs in health and diseases 
 
This understanding of cellular mechanisms of regulatory miRNAs and connections 
of their dysregulation with so many pathophysiological conditions suggest that 
possibility of exploiting miRNAs and their regulator stakeholders as a target to 
address and cure multiple pathophysiological conditions or diseases. 
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1.3 Current methods to regulate miRNAs 
Several approaches have been developed to regulate the level or activity of 
miRNAs is based upon level and activity of mature miRNA, include using miRNA 
sponges as an alternative for miRNA targets or using small molecules or 
chemically modified antisense oligonucleotides as inhibitors. 
miRNA sponge  
This technique is based upon the overexpression of a transcript containing several 
artificial miRNA binding sites, each of which acts as binding site for endogenous 
miRNAs and altogether as sponges. As a result, the expression of target mRNA 
remains unaffected. Although this method is useful to investigate the miRNAs 
function in vitro, its dependency on cellular machinery to overexpress miRNA 
target sites and the requirement of special delivery methods for cellular uptake, 
makes it difficult for in vivo studies.55-58  
Small molecule inhibitors  
Several small molecule-based miRNA inhibitors have been discovered and 
developed to control miRNA expression and function. Small molecules act mainly 
through regulation on the expression and maturation of targeted miRNAs. 
Aminoglycosides have long been regarded as good RNA binders, several of these 
aminoglycosides and modified aminoglycosides are reported as miRNA 
biogenesis inhibitors.59,60 Xanthone derivatives and other small molecules 
incorporating some aromatic and heteroaromatic moieties obtained by screening 
a library of small molecules against miRNA precursors have also been reported as 
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efficient miRNA biogenesis as well as functional inhibitors.61-66 Aza-flavones are 
also found to be an important class of miRNA inhibitors.67 Although some of the 
small molecule inhibitors are found to be effective in regulating miRNA function or 
expression, the relatively high EC50 value, the difficulty to design inhibitors based 
on target RNA sequences, and the limited understanding about the molecular 
mechanisms of inhibition by these molecules pose great challenges in therapeutic 
applications of this method.59-67 
Antisense oligonucleotides 
Antisense oligonucleotide (ASO) technology has been the most commonly used 
method for miRNA regulation. One major advantage of using ASOs as oppose to 
small molecules is that the sequence-based design of inhibitors can be easily 
achieved. Most ASOs are designed to target miRNAs (e.g. anti-miRs) that inhibit 
the miRNA function or production by steric disruption of the interaction between 
miRNAs or pre-miRNAs and their protein partners (e.g. RNA-induced silencing 
complex (RISC) or Dicer), which lead to the inhibition of either their binding to 
endogenous mRNA targets or the maturation of miRNAs. Several chemically 
modified ASOs have been developed as anti-miRs to enhance their stability and 
binding affinity. Modifications like 2’-OMe are resistance to endonuclease, 
however, susceptible to degradation by exonuclease, which limits its applications. 
Phosphorothioate modification converting a non-bridging oxygen atom into sulfur 
offers an excellent exonuclease resistance and better cellular uptake. Mixed 
oligonucleotides with both 2’-OMe and phosphorothioate modifications have been 
used commonly as anti-miRs. Additionally, modifications like 2’-fluoro (2’-F), 2’- 
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methoxyethyl (2’-MOE) and locked nucleic acid (LNA) are also used to improve 
nuclease resistance while maintaining strong DNA/RNA binding affinity (Fig 1.5). 
These modifications can be used alone or mixed to tune the efficiency of anti-miRs. 
Backbone modifications (MO, PNA), although being used widely, these ASOs 
Figure 1.4: miRNA regulation strategies3 
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typically have problem with cellular delivery, special methods are required to 
deliver these ASOs into cells.3 
Most of these ASOs act through competing with strong macromolecular interaction 
between miRNAs and their binding proteins. To offer effective competition, long 
ASOs are typically used (e.g. 25 nucleotides in case of MOs). Despite of 
consistency and efficacy, using long ASOs usually lead to off-target binding to 
other miRNAs, mRNA and other cellular RNAs.  
Although with longer ASOs, we supposed to have fewer perfectly matched targets 
in the transcriptome, under physiological conditions, each ASO can interact with 
any RNAs through imperfect base pairing similar to non-specific priming observed 
in PCR at low annealing temperatures. As a result, small interfering RNA (siRNA) 
and miRNA mimetic including LNA and antagomirs have been shown to give 
Figure 1.5:  Chemically modified nucleotides83 
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unwanted off-target effects.68-82 Such imperfect pairing is used by miRNA to 
regulate up to hundreds of mRNAs in the cells. Besides off-target inhibition, current 
ASOs cannot be used to dissect differential functions among miRNAs of same 
family (with similar mature sequence), along with the poor cellular delivery and 
distribution limit the utility of this strategy.  
To address the issues of current ASO methods, my thesis is focused on the design 
and development of a new class of bi-functional miRNA regulators with distinct 
chemical structures and inhibitory mechanisms. 
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Chapter 2  
Developing ASO-based bi-functional miRNA regulators  
2.1 Introduction  
We designed a unique class of bi-functional miRNA regulators that blocks the 
Dicer-mediated maturation of miRNAs. Since Dicer knockdown causes serious 
biological defects including cell toxicity,4,5 the bi-functiuonal molecules were 
designed to block the Dicer activity by selectively inhibiting the catalytic turnover 
of unique Dicer-pre-miRNA complexes to block the maturation of miRNA of 
interest. Dicer is a member of the ribonuclease III family that processes stem-loop 
double stranded pre-miRNAs (~ 70 nts) into mature miRNAs. 
 
Figure 2.1: Downregulation of a specific miRNA through inhibiting its pre-miRNA cleavage 
by Dicer. (A bi-functional miRNA regulator selectively binds to the loop sequence of targeted pre-
miRNA (red) and is brought to the associated Dicer. The inhibitor module in the regulator blocks 
the pre-miRNA cleavage by Dicer only at the targeted pre-miRNA.) 
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The designed bi-functional miRNA regulators contain a low affinity Dicer inhibitor 
covalently linked to a high affinity sequence-specific pre-miRNA recognition 
molecule to recognize and inhibit only specific Dicer molecules that would catalyze 
the cleavage of a specific pre-miRNA. At low concentrations, the weak binding 
Dicer inhibitor cannot inhibit Dicer activity on its own so that Dicer cellular function 
will remain intact. When bi-functional regulators bind to the loop region of targeted 
pre-miRNAs, the Dicer inhibitor will be placed at the active site of specific Dicer, 
with a dramatically increased local effective concentration of the Dicer inhibitor to 
achieve Dicer inhibition. There are many reported RNase III inhibitors that can 
potentially be used as our low affinity Dicer inhibitor through a two divalent metal 
ion catalyzed mechanism1-3  with IC50 ranging from low to high µM concentration.6,7  
Commercial custom synthesized morpholino oligonucleotides can were used as 
the high affinity pre-miRNA recognition module. MOs have standard nucleic acid 
bases linked to a morpholine rings connected through uncharged 
phosphorodiamidates instead of phosphodiester 
linkages (Figure 2.2), which gives the better binding 
affinity to RNAs as well as better nuclease resistance8-
13. As oppose to the standard long MOs (25-mer/ 
commonly used, we incorporated a short version of 
MOs 14-mer or less) to target the pre-miRNA loop 
region. We hypothesis that individual Dicer inhibitor 
unit and the pre-miRNA recognition unit by itself would not be inhibitory unless 
being coupled together to form the bifunctional regulator. 
Figure 2.2 Morpholino12 
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The function of miRNAs is usually dynamic and cellular context dependent. To 
achieve spatiotemporal regulation of miRNAs, we also developed light controllable 
bi-functional miRNA regulators. ASOs such as morpholinos have poor cell 
permeability and enhanced stability in cells. They cannot get in the cell readily, and 
once delivered into the cells, the inhibitory effect of ASOs can be long lasting. To 
offer a spatiotemporally inactivatable miRNA regulator, we designed a light 
deactivatable version of bi-functional regulator by connecting the pre-miRNA 
recognition unit with the Dicer inhibition unit through a photo-cleavable linker. Once 
cleaved by light the bifunctional molecule will be fragmented into two inactive units 
and the inhibitory effects reversed.  
Furthermore, a light activatable bi-functional regulator can be generated by 
masking the Dicer inhibition unit with a photo-cleavable caging group. Such 
regulators will remain inactive until the caging group is removed by a specific 
Figure 2.3: Design of light controllable bifunctional molecules 
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radiation of light to release the active bi-functional miRNA regulator. By combining 
both of these light activation and inactivation strategies, a bi-functional miRNA 
regulator with precise spatiotemporal control can be created (Figure 2.3). 
2.2 Results and discussions  
Recognition module  
To start our investigation about the bi-functional strategy, we choose to use MO as 
our pre-miRNA recognition unit, which is designed to be complementary to the 
single stranded hairpin loop region of pre-miRNA of interest. This will facilitate the 
targeting of exposed sequences and avoid the binding competition with Dicer at 
the Dicer cleavage site in the double stranded region. 25-mer MOs (Tm ~ 90°C)14 
are currently used to provide the desired knockdown effects, which cause off target 
inhibitions under physiological condition likely due to imperfect pairing to many 
RNA species in cells. To address this, we used shorter 14-mer MOs (Tm ~60°C)14 
as the pre-miRNA recognition unit, which we expect to have reduced off targets 
and still form sufficiently stable duplex with pre-miRNAs in cells. Since MOs longer 
than 15-mer have been found to have observable biological effects, 14-mer MO 
(or shorter) should not block Dicer-mediated pre-miRNA processing by itself. 
To investigate if a 14-mer MO is sufficient to specifically match a unique pre-
miRNA in sequence, we performed a BLAST analysis using 14-mer sequences 
chosen from the hairpin-loop region of miRNAs associated with human diseases. 
Among all the tested sequences, each only matches one unique pre-miRNA. 
Although many of these sequences also exist in mRNAs (Figure 2.4), our unique 
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bi-functional design, which exerts effects through Dicer enzymatic inactivation 
instead of steric interference, minimizes the interference on mRNAs. 
We have chosen miRNA-21 as our initial target for the study, which was first 
identified in 2005 as the most commonly and highly upregulated miRNA in human 
brain tumor glioblastoma15. Since then many researchers studied about this miR-
21 in various fields including oncology, stem cell and aging biology and 
development, making it one of the most studied miRNAs (Table 2.1).  
Disease cells miR-21 
expression 
Biological process miR-21 
targets 
Glioblastoma Up-regulation  Invasion and cell growth PDCD4, 
RECK, 
Figure 2.4:  BLAST analysis of 14-mer pre-miRNAs loop sequences 
27 
 
TIMP3, 
NFIB, 
APAF1, 
STAT3 
Breast cancer Up-regulation Cell growth, apoptosis, 
angiogenesis and invasion 
PDCD4, 
TPM1, 
Maspin 
Lung cancer Up-regulation   
Pancreas cancer Up-regulation   
Ovarian cancer Up-regulation   
Cervical cancer Up-regulation   
Colorectal cancer Up-regulation Cellular outgrowth, migration, 
invasion and metastasis 
PDCD4, 
NFIB, 
SPRY2 
Hepatocellular 
carcinoma 
Up-regulation Cell migration and invasion and 
proliferation 
PTEN 
Stomach/gastric 
cancer 
Up-regulation  RECK 
Prostate cancer Up-regulation   
Thyroid carcinoma Up-regulation   
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Leukemia Up-regulation   
B-cell and Hodgkin 
lymphoma 
Up-regulation   
Cardiovascular Up/down 
regulation 
Vascular smooth muscle cell 
proliferation and apoptosis, 
cardiac cell growth and death, 
and cardiac fibroblast functions 
PDCD4, 
PTEN, 
SPRY1, 
SPRY2  
 
Table 2.1:  miR-21 regulation and function in human diseases15-21 
 
Figure 2.5: Hair-pin secondary structure of hsa-pre-miR-2122-25 (yellow highlighted region is 
the sequence we want to target through our recognition module i.e.  MO)
 
Based upon the sequence of hsa-premiR-21 (Figure 2.5), we have designed the 
following MOs with a 3’-azido group, which can be custom synthesized 
(GeneTools, Philomath, OR), to be used as our pre-miR-21 recognition unit, 
5’-CCATGAGATTCAACAG-3’                 (16-mer MO-21) 
5’-CCATGAGATTCAACA-3’                    (15-mer MO-21) 
5’-CATGAGATTCAACA-3’                       (14-mer MO-21) 
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5’-TGAGATTCAACA-3’                            (12-mer MO-21) 
5’-AGATTCAACA-3’                                 (10-mer MO-21) 
Furthermore, we used a 25-mer MO-21 (as below) designed by GeneTools as 
miR-21 inhibitor, which is complementary to both mature strand sequence and part 
of the loop region as a positive control. 
AGTCAACATCAGTCTGATAAGCTAC       (25-mer MO-21)    
Comparison of off-target binding of 14-mer versus 25-mer MO against 
cellular RNAs in vitro  
We expect that under physiological temperature, a 25-mer MO will likely target a 
lot more different mRNAs through imperfect pairing than a 14-mer, which is a 
potential source of causing unwanted biological effects.  
To test if a 14-mer MO indeed 
recognize less RNAs in the 
transcriptome, we got biotin-
labeled 14-mer and 25-mer 
MOs for recognizing pre-miR-
21 by click chemistry between 
the azido-MOs and an alkyne-
group attached biotin. These 
MOs were incubated separately with total mRNAs purified (using Oligotex mRNAs 
kit from QIAGEN, Hilden, Germany) from HeLa cells (known to express miR-21) 
at 37°C and the bound RNA species were pull-downed by streptavidin beads. We 
Figure 2.6: Numbers of pulled-down mRNAs by 
biotinylated 14-mer and 25-mer MOs designed for 
miR-21 
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Figure 2.7: Some examples of RNase III inhibitors6,7. 
had also incubated biotin only (without MO) with these RNAs as a negative control. 
After washing, the bound RNAs with beads were eluted and submitted for RNA-
seq (using Illumina NextSeq 500 for pair-end sequencing 75bp X 2, 130 million 
read). As an indication of the number of RNAs each molecule target, we focused 
on mRNAs being pulled down in each condition. Obtained reads were aligned 
against human reference genome, annotated and counted. After removing 
common RNAs found in biotin-only pull down, we found that the 14-mer MO indeed 
bound much less mRNAs than 25-mer MO (Figure 2.6). 
Inhibitor and bifunctional molecules    
To generate a bi-functional regulator, we chose to use reported N-substituted 
Phthalimides (-OH, -OMe, -NH2) (e.g. compound 1, 2 and 3, Figure 2.7) as our 
Dicer inhibition unit, which have been reported to inhibit RNase III family enzymes 
by chelating two divalent metal ions (Mg2+ in Dicer) in the active site, although 
rather poorly (IC50 > 500 µM).6 Furthermore, some other more potent RNase III 
inhibitors (low µM) e.g. N-hydroxyimides, diketobutanoates or flutimides 
(compound 4, 5 and 6, Figure 2.7)6,7 can also be used. 
 
 
 1, 2 and 3 (R = OH, OMe and NH2)               4                       5                  6               
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We expect that the length and the structure of linkers may also play a crucial role 
in the bi-functional molecules activity in addition to the Dicer inhibition unit and the 
pre-miRNA recognition unit. As a result, we synthesized and tested several bi-
functional miR-21 regulators with different linkers to connect the two functional 
units.  
To synthesize bi-functional regulators, we synthesized alkyne-equipped N-
substituted phthalimides (-OH, -OMe, -NH2) (compound 1, 2 and 3) that were 
subsequently linked to azido-MOs custom synthesized for pre-miR-21 through 
copper catalyzed click chemistry26 (compound 10 to 13) (Scheme 2.1). To test the 
importance of the distance between the Dicer inhibition unit and the pre-miRNA 
Scheme 2.1: Synthesis of bi-functional miRNA regulators with different linker length 
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recognition unit, we synthesized another bi-functional molecule with longer linker 
(21 atoms vs. 10 atoms) to connect the two functional units as shown in Scheme 
2.1 (Compound 14). 
All synthesized molecules were purified by HPLC or silica gel chromatography and 
fully characterized before biological assays to ensure the purity (without the 
contamination of other organic solvents or reagents that were used during 
synthesis). Using click chemistry to assemble the bi-functional molecules will 
enable us to generate the new bi-functional regulators for other miRNAs by 
switching the pre-miRNA recognition units with MOs designed for other pre-miRNA 
sequences. 
Stability of bifunctional molecules  
To test the stability of the bi-functional molecule, we incubated compound 12 in the 
HEPES buffer (pH 7.4, physiological condition) for up to 5 d and phosphate buffer 
(pH 6, endosome release condition27) for up to 48 h and then analyzed by HPLC. 
We found that the synthesized bi-functional regulator is chemically stable during 
Figure 2.8: Chemical stability of the bi-functional regulator by HPLC at different pH 
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tested period based on the finding that the peak corresponding to compound 12 in 
HPLC chromatogram did not change after the incubation (Figure 2.8).  
To further explore the binding of our pre-miR-21 recognition units (i.e. MOs) with 
pre-miR-21, gel shift assay was performed. All the recognition units, the 
bifunctional molecule (12), or the positive control (25MO-miR-21) and negative 
control (25MO-miR-29b1) were incubated with P32-internally labelled premiR-21 
at 37 °C for 1.5 h and then subjected to 15% non-denaturing polyacrylamide gel 
analysis, followed by exposure to photographic plate and imaging using PMI1 
(Figure 2.9). Gel shift assays showed 14-mer MO (or longer), as well as the bi-
functional molecule, stably bound to pre-miR-21 whereas 12-mer MO or 25-mer 
MO designed for another pre-miRNA did not bind pre-miR-21. These results 
confirm that the 14-mer MO is sufficient to 
recognize target pre-miRNA. 
Dicer cleavage inhibition assay of bifunctional 
molecules 
Our bi-functional miRNA regulators are designed 
to inhibit Dicer processing of pre-miRNA. To 
evaluate Dicer activity on pre-miRNA processing, 
we developed an in vitro assay that includes the 
recombinant human Dicer proteins (from 
Genlantis, San Diego, CA) and 32P-labeled pre-miRNA (produced by the in vitro 
transcription from DNA template with T7 promoter using T7 RNA polymerase). By 
using this method, we can successfully examine Dicer-mediated processing of pre-
Figure 2.9: Gel shift assay for 
recognition modules and 
bifunctional molecule (12) 
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miRNAs (e.g. pre-miR-21) (~ 70 nts) into short mature miRNA (~22 bps) using 16% 
denaturing polyacrylamide gel electrophoresis with Decade marker system 
(Thermo Fisher Scientific) followed by exposure to photographic plate and imaging 
using PMI1 (Figure 2.10).  
We then used this assay to test 
the activity of bi-functional 
regulators, different MO, 
inhibition units and the control 25-
mer MO against Dicer-mediate 
processing of pre-miR-21, We 
found that none of the recognition 
units significantly inhibit the 
processing (up to 100 µM, Figure 2.11). Similarly, none of the synthesized Dicer 
inhibition units (compound 7 to 9 up to 1mM) inhibit the processing. In this figure, 
25 MO (C) is the scrambled negative control 25-mer MO designed by Gene-Tools 
(Figure 2.12). On the contrary, the bi-functional miR-21 regulator with 14-mer MO 
(compound 12) blocked the Dicer-mediated pre-miR-21 cleavage process at 10 
μM and above, showing a potency improvement of at least 100 folds as compared 
to its corresponding inhibition unit (compound 7) (Figure 2.13). Interestingly, the 
bi-functional regulator with the longer flexible linker (compound 14), showed a 
much lower activity as compared to compound 12 (Figure 2.13). 
Figure 2.10: Dicer-mediated pre-miRNA 
cleavage 
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Figure 2.11: Dicer cleavage assay for recognition units A) Gel electrophoresis of cleaved 
and un-cleaved pre-miR-21 B) quantification of pre-miR-21 band in each lane (3-independent 
experiments were used to calculate the error bar) 
Figure 2.12: Dicer cleavage assay for inhibition units A) Gel electrophoresis of cleaved and 
un-cleaved pre-miR-21 B) quantification of pre-miR-21 band in each lane (3-independent 
experiments were used to calculate the error bar) 
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This suggests that the importance of linker in our bi-functional molecule and the 
decreased activity may due to the entropic penalty introduced by using a longer 
and flexible linker. Encouragingly, bi-functional regulator with the short linker 
(compound 12) showed a better activity than the 25-mer MO control at the similar 
concentration (Figure 2.13). Overall, we showed that the bi-functional design can 
give functional regulators to block miRNA maturation. The 14-mer MO can give 
sufficient recognition without inhibiting the process by itself. The linker plays an 
important role in the activity. To further explore, the effects of the MO length in the 
activity of bi-functional molecules, we synthesized bi-functional molecules with 
shorter or longer MOs range from 10-16-mer (Scheme 2.1) and tested their activity 
to block miRNA maturation in vitro.  
Figure 2.13: Dicer cleavage assay for bifunctional molecules A) Gel electrophoresis of 
cleaved and un-cleaved pre-miR-21 B) quantification of pre-miR-21 band in each lane (3-
independent experiments were used to calculate the error bar) 
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From the results, we found that bi-functional regulators with MOs shorter than 14-
mer (compound 10 and 11) have decreasing activity corresponding to the MO 
length (Figure 2.14A). Surprisingly, compound 13 (with 16-mer MO) has 
decreased activity when compared to compound 12 (with 14-mer MO) (Figure 
2.13B). These results suggest that the pre-miRNA recognition unit plays a key role 
in the activity of the bi-functional regulator. 
 
Figure 2.14: Dicer cleavage assay for different length recognition unit bifunctional 
molecules A) and B) Gel electrophoresis of cleaved and un-cleaved pre-miR-21 C) and D) 
quantification of pre-miR-21 band in each lane (3- independent experiments were used to calculate 
the error bar) for A and B respectively 
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Generating bi-functional regulators for other miRNAs 
Based on the findings shown above, we hypothesize that new bi-functional 
regulators can be generated to target other miRNAs by swapping the pre-miRNA 
recognition unit. To test this, we synthesized bi-functional regulators for hsa-miR-
29s by replacing the MO unit in the bi-functional miR-21 regulators with an MO 
designed to target the loop sequence of pre-miR-29b-1. There are four hsa-miR-
29, namely hsa-miR-29a, hsa-miR-29b-1, hsa-miR29b-2 and hsa-miR-29c in the 
family. Out of four members, miR-29a, miR-29b1 and miR-29c are the most 
abundant and functionally important miRNAs.1,28-37 
hsa-pre-mir-29a 
5’AUGACUGAUUUCUUUUGGUGUUCAGAGUCAAUAUAAUUUUCUAGCACCA
UCUGAAAUCGGUUAU 3’ 
hsa-pre-mir-29b-1 
5’CUUCAGGAAGCUGGUUUCAUAUGGUGGUUUAGAUUUAAAUAGUGAUUG
UCUAGCACCAUUUGAAAUCAGUGUUCUUGGGGG 3’ 
hsa-pre-mir-29c 
5’AUCUCUUACACAGGCUGACCGAUUUCUCCUGGUGUUCAGAGUCUGUUU
UUGUCUAGCACCAUUUGAAAUCGGUUAUGAUGUAGGGGGA 3’ 
Figure 2.15: Nucleotide sequence of hsa-pre-miR-29 family (The yellow highlighted regions 
represent the loop-sequences, green regions represent the 3p-mature sequences and pink regions 
represent the less abundant 5p-mature sequences)  
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MiR-29 family members share almost identical mature sequences but each has 
unique loop sequence among others (Figure 2.16). It is known that miR-29a and 
miR-29b-1 are both expressed in Hela cells. However, miR-29a resides in 
cytoplasm and miR-29b-1 is transported to the nucleus.38 They also have different 
half-life during cell cycles.38 It suggests that miRNAs within the same family 
potentially have different functions. 
Since the majority of miRNA genes (~ 70 %) are reported to be grouped into 
miRNA families, it is very important to dissect the function of each member in a 
family. Current miRNA regulators cannot selectively target individual members 
within the same family because most of these techniques target the highly 
homologous mature miRNA sequence shared by miRNAs in the same family. Our 
bi-functional miRNA regulators targeting the unique loop sequences might be an 
efficient way to distinguish individual miRNAs in a family.  
To develop a new regulator for miR-29b1 from the bi-functional miR-21 regulator, 
we designed our recognition unit (a 3’-azido14-mer MO) to be complementary to 
the loop region of pre-miR-29b-1. We also obtained the 25-mer MO antagomir from 
Gene tools as a control.8-12  
Figure 2.16: Sequence alignment of mature and loop sequences of different hsa-miR-
29s (black highlighted nucleotides represents the similar sequence) 
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5’-AACACTGATTTCAAATGGTGCTAGA-3’        (25-mer MO-29b1 antagomir) 
5’-ACAATCACTATTTA-3’                                     (14-mer MO-29b1) 
We synthesized the bi-functional regulator (compound 15) by clicking the azido 14-
mer MO for miR-29b-1 and inhibition unit (compound 7) and tested its activity using 
the Dicer cleavage assay.  
 
We observed that compound 15 can completely inhibit the processing of pre-miR-
29b-1 by Dicer and is more potent than the 25-mer MO control at the same 
Figure 2.17: Dicer cleavage assay for pre- miR-29b1 A) and B) Gel electrophoresis of cleaved 
and un-cleaved pre-miR-29b1 C) and D) quantification of pre-miR-29b1 band in each lane (3-
independent experiments were used to calculate the error bar) for A and B respectively 
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concentration (Figure 2.17). These results indicate that new bi-functional miRNA 
regulators can be quickly generated by switching the pre-miRNA recognition units.  
Design and synthesis of light controllable bifunctional molecule    
To develop a light controllable version of bi-functional regulators to achieve 
spatiotemporal control, we incorporated a photo-cleavable 4, 5-dimethoxy-2-
nitrobenzyl (DMNB) group (cleavable by 365nm light) in to the linker connecting 
the inhibition unit and the recognition unit (compound 16). This will allow a rapid 
light inactivation of the bi-functional molecules by separating the two functional 
units. We also synthesized the corresponding bi-functional molecule (compound 
17) by clicking the azido 14-mer MO to compound 16. Furthermore, to achieve light 
activation, it is possible to attach a photo-cleavable [7-diethylaminocoumarin-4-yl] 
methyl (DEACM) group to the inhibitor unit at the N-hydroxy group (e.g. compound 
18) that can be removed by the 405nm light.39-49 
Scheme 2.2: Synthesis of light-controllable bi-functional regulator 
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Test the light cleavage efficiency and inactivation of bi-functional molecule 
To test the light induced cleavage, we illuminated the synthesized light-controllable 
molecule (compound 16) with 365 nm light for different time periods and did HPLC 
analysis. We found that the DMNB group on compound 16 can be efficiently 
cleaved by 365 nm light (Figure 2.18).  
To test if the light irradiated DMNB-containing bi-functional regulator can be 
inactivated, we compared the inhibitory activity of compound 16 before and after 
365nm light irradiation (10 min) using the Dicer cleavage assay. We observed that 
the activity of the light controllable bi-functional molecule (compound 16) was 
abolished after light irradiation (Figure 2.19). 
Figure 2.18: HPLC analysis cleavage efficiency of compound 16 by using 365 nm light  
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Facilitating cellular delivery of bi-functional regulators 
One of the main problems associated with antisense strategy is the cellular 
delivery. One common method used to deliver MO is the use of a delivery agent 
‘Endo-porter” (designed by Gene-tools).50-53 To test the cellular delivery efficiency, 
we synthesized a model bi-functional regulator with a 14-mer MO and a fluorescent 
probe (compound 19) (Scheme 2.3). 
 
Figure 2.19:  Dicer cleavage assay for active vs deactivated light controllable bi-
functional molecule A) Gel electrophoresis of cleaved and un-cleaved pre-miR-21 B) 
quantification of pre-miR-21 band in each lane (3-independent experiments were used to calculate 
the error bar) 
Scheme 2.3: Synthesis of the fluorescent bi-functional MO probe. 
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We tested the delivery of compound 19 (10 µM) into Hela cells using Endo-Porter 
following vendor’s protocol and observed the fluorescence signal under a 
fluorescence microscope in presence of Endo-porter. We did observe the delivery 
of the model molecule inside the cells although the level was very low and not very 
efficient (it took about 72h before a fluorescence signal can be observed in the 
cell) (Figure 2.20).  
We then tested using Endo-porter to deliver the bi-functional miR-21 regulator 
(compound 12) into HeLa cells and examined the changes of the cellular miR-21 
level with or without the treatment of the regulator. Unfortunately, no significant 
cellular activity was observed by RT-qPCR (monitoring miR-21 levels) and western 
blot analysis (monitoring PDCD4 levels, a miR-21 target). The lack of cellular 
activity is likely due to the ineffective delivery method, or insufficient activity. In the 
next part of my work, I am focusing on optimizing the bi-functional regulators, 
including the delivery methods.  
 
 
 
Figure 2.20: Cell uptake of the fluorescent bi-functional MO probe (compound 19) in Hela 
cells (A= none, B= fluorophore compound only, C= compound 19 only and D= compound 19 + 
Endo-porter) after 72 hrs. 
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2.3 Conclusion   
In this Chapter, we described the design and development of a unique class of bi-
functional regulators. We showed that the bi-functional strategy improves the 
activity of individual Dicer inhibition and pre-miRNA recognition units. We identified 
compound 12 the most potent bi-functional molecule.  
Furthermore, with the intention to develop spatiotemporally controlled miRNA 
regulation tools, we converted compound 12 into light controllable molecule by 
incorporating a light cleavable group in its linker to make it become light 
inactivatable (compound 17).  
Additionally, the current delivery method, Endo-porter, is found to be inefficient to 
deliver our bi-functional molecules and new delivery methods are required.  
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2.4 Methods 
Bifunctional molecules synthesis 
 
Compound 2 was synthesis as described in the literature 1. 
1-Hexynoic acid (1.2 g; 11.24 mmol) and BOP reagent (5.7 g; 13 mmol) were 
dissolved in CH2Cl2 (15 mL). After 10 min, 2, 2’-(Ethylenedioxy) diethylamine (10 
g; 67.47 mmol) in CH2Cl2 (60 mL) was added. The mixture was stirred at room 
temperature for 3 hours. A saturated NaHCO3 aqueous solution (pH 9, 50 mL) 
was added and organic layer was extracted several times by CH2Cl2 (50 mL). The 
organic phase was filtered, dried with Na2SO4 and evaporated under reduced 
pressure. The residue was purified by silica gel column chromatography 
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(CH2Cl2/MeOH/Triethylamine, 95/5/0.1) to provide 2 g of (2) (yield 73 %) as a 
yellow oil. Rf: 0.31 (CH2Cl2/MeOH/Triethylamine, 9/1/0.1). 
Compound 4 was made from compound 3 follow the routine methods. 
Compound 5 
Propargylamine (55 mg, 1 mmol) was dropped into a solution containing 
Compound 4 (211 mg, 1 mmol) in dry THF under ice bath. Followed by Et3N (121 
mg, 1.2 mmol). Continue stir 3 hours. Remove the solvent under 30 °C. NH2NH2 
(70 mg, 1 mmol) and pyridine (20 mL) were added to the flask and stirred 15 h at 
90 °C. Then remove the solvent, wash with water and dry it. Yield: 68 %. 1H NMR 
(DMSO-d6, 300 MHz): 11.66 (bs, 2H), 9.39 (t, J= 10.8 Hz, 1H), 8.57 (s, 1H), 8.31-
8.28 (dd, J= 8.4, 1.8 Hz, 1H), 8.14-8.11 (d, J= 8.1 Hz, 1H), 4.11-4.08 (q, J= 7.8 Hz, 
2H), 3.17-3.15 (t, J= 4.8 Hz, 1H). 13C NMR (DMSO-d6, 75 MHz): 164.80, 137.13, 
131.21, 128.76, 127.42, 125.54, 124.45, 80.98, 73.07, 28.80. TOF-HRMS (m/z) 
found (calcd.) for C12H9N3O3 (M): [M+H]+, 244.0721 (244.0722). 
Compound 6 
Propargylamine (55 mg, 1 mmol) was dropped into a solution containing 
Compound 4 (211 mg, 1 mmol) in dry THF under ice bath. Followed by Et3N (121 
mg, 1.2 mmol). Continue stir 3 hours. Remove the solvent under 30 °C. 
NH2OCH3/HCl (84 mg, 1 mmol) and pyridine (20 mL) were added to the flask and 
stirred 15h at 90 °C. Then remove the solvent and purify on silica gel. Yield: 75 %. 
1H NMR (DMSO-d6, 300 MHz): 9.34-9.30 (t, J= 10.8 Hz, 1H), 8.30-8.26 (m, 2H), 
7.96-7.94 (dd, J= 7.8, 0.6 Hz, 1H), 4.11-4.09 (q, J= 7.8 Hz, 2H), 3.97 (s, 3H), 3.19-
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3.18 (t, J= 4.8 Hz, 1H). 13C NMR (DMSO-d6, 75 MHz): 164.03, 162.37, 162.30, 
139.09, 133.87, 130.95, 128.99, 123.43, 121.55, 80.74, 73.25, 65.42, 28.83. TOF-
HRMS (m/z) found (calcd.) for C13H10N2O4 (M): [M+H]+, 259.0710 (259.0719); 
[2M+Na]+, 539.1189 (539.1179).  
Compound 7 
Propargylamine (55 mg, 1 mmol) was dropped into a solution containing 
Compound 4 (211 mg, 1 mmol) in dry THF under ice bath. Followed by Et3N (121 
mg, 1.2 mmol). Continue stir 3 hours. Remove the solvent under 30 °C. 
NH2OH/HCl (70 mg, 1 mmol) and pyridine (20 mL) were added to the flask and 
stirred 15 h at 90 °C. Then remove the solvent and purify on silica gel. Yield:75 %. 
1H NMR (DMSO-d6, 300 MHz): 10.93 (s, 1H), 9.34-9.30 (t, J= 10.8 Hz, 1H), 8.29-
8.25 (m, 2H), 7.95-7.92 (d, J= 7.5 Hz, 1H), 4.11-4.08 (q, J= 7.8 Hz, 2H), 3.17-3.16 
(t, J= 5.1 Hz, 1H). 13C NMR (DMSO-d6, 75 MHz): 164.15, 163.53, 163.46, 138.97, 
133.65, 131.068, 129.11, 123.16, 121.31, 80.73, 73.21, 28.78. TOF-HRMS (m/z) 
found (calcd.) for C12H8N2O4 (M): [M+H]+, 245.0560 (245.0562). 
Compound 8 
Copper (I) iodide (50 nmol), Sodium Ascorbate (VcNa) (100 nmol) and Tris[(1-
benzyl-1H-1,2,3-triazol-4-yl) methyl] amine (50 nmol) were mixed together in 
DMSO. Followed by Morpholinos (50 nmol) in water, small molecule (100 nmol) in 
DMSO. The mixture was shacked and incubated 15h. Separate on HPLC. 
8a: MS (modify protein way) (m/z) found (calcd.): 3843.8 (3844.1).  
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8b: MS (modify protein way) (m/z) found (calcd.): 4529.9 (4529.1).  
8c: MS (modify protein way) (m/z) found (calcd.): 5183.8. (5184.1).  
8d: MS (modify protein way) (m/z) found (calcd.): 5501.5 (5501.1).  
8e: MS (modify protein way) (m/z) found (calcd.): 5856.8 (5857.1).  
Compound 9 
Compound 9 was synthesized follow the method as described for compound 7. 
Yield: 35 %. 
1H NMR (MeOD, 300 MHz): 8.27-8.25 (m, 2H), 7.95-7.92 (d, J= 7.8 Hz, 1H), 3.71-
3.63 (m, 8H), 3.58-3.54 (t, J= 10.5 Hz, 2H), 3.37-3.33 (t, J= 12.9 Hz, 2H), 2.33-
2.28 (t, J= 14.7 Hz, 2H), 2.24-2.18 (m, 3H), 1.83-1.74 (m, 2H). 13C NMR (MeOD, 
75 MHz): 164.15, 163.53, 163.46, 138.97, 133.65, 131.068, 129.11, 123.16, 
121.31, 80.73, 73.21, 28.78. TOF-HRMS (m/z) found (calcd.) for C21H25N3O7 
(M): [M+Na]+, 454.1588 (454.1590). 
Compound 10 
Compound 10 was synthesized follow the method as described for compound 8. 
MS (modify protein way) (m/z) found (calcd.): 5371.5 (5371.2). 
Synthesis for bi-functional molecule for miR-29-b-1 
Same as in method described for compound 8 but using 14 MO-29b1 with 
compound 7. 
MS (modify protein way) (m/z) found (calcd.): 5134.96 (5,135.056). 
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Light cleavable bifunctional molecule synthesis 
Compound 2 was made from compound 1 following the routine methods. 
Compound 4 
Compound 3 (1.69 g, 10 mmol) and K2CO3 (1.66 g, 12 mmol) were stirred in DMF 
10 min at 90 °C. Propargyl bromide (80 wt. % in toluene, 12 mmol) was added to 
above solution. Continue stirring 2h. Extract with Ethyl acetate/ brine. Purify on 
silica gel. Yield: 98 %. 1H NMR (Acetone-d6, 300 MHz): 8.18-8.15 (d, J = 9.0 Hz, 
1H), 7.56-7.55 (d, J = 1.5 Hz, 1H), 7.11-7.07 (dd, J = 9.0, 2.4 Hz, 1H), 5.03 (d, J= 
5.4 Hz, 2H), 4.97-4.96 (d, J= 2.1 Hz, 2H), 4.70-4.66 (t, J= 11.1Hz, 1H), 3.18-3.16 
(t, J= 3.6 Hz, 1H). 13C NMR (Acetone-d6, 75 MHz): 162.00, 142.14, 140.47, 
127.20, 113.85, 113.02, 77.86, 76.99, 60.95, 56.06. TOF-HRMS (m/z) found 
(calcd.) for C10H9NO4 (M): [M+Na]+, 230.0423 (230.0429). 
Compound 5 
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Compound 4 (1.03 g, 5 mmol) was dropped into a solution containing Compound 
4 (1.05 g, 5 mmol) in dry THF under ice bath. Followed by Et3N (5.56 g, 5.5 mmol). 
Continue stir 5 hours. Remove the solvent under 30 °C. NH2OH/HCl (0.35 g, 5 
mmol) and pyridine (50 mL) were added to the flask and stirred 15 h at 90 °C. Then 
remove the solvent and purify on silica gel. Yield: 45%. 1H NMR (Acetone-d6, 300 
MHz): 8.57-8.54 (d, J = 7.7 Hz, 1H), 8.41 (s, 1H), 8.29-8.26 (d, J = 9.0 Hz, 1H), 
8.03-8.00 (dd, J= 7.8, 0.6 Hz, 1H), 7.47-7.46 (d, J= 2.7 Hz, 1H), 7.25-7.21 (dd, J= 
9.0, 2.8 Hz, 1H), 5.85 (s, 2H), 5.00-4.99 (d, J= 2.4 Hz, 2H), 3.22-3.20 (t, J= 4.8 Hz, 
1H). 13C NMR (Acetone-d6, 75 MHz): 163.99, 162.82, 161.86, 141.14, 135.59, 
135.10, 134.66, 133.29, 129.94, 127.75, 123.36, 115.03, 114.48, 77.66, 77.44, 
64.12, 56.28. TOF-HRMS (m/z) found (calcd.) for C19H12N2O8 (M): [M+Na]+, 
419.0496 (419.0491). 
Compound 7 
Compound 5 (0.396 g, 1 mmol) and 1, 8- Diazabicyclo[5.4.0]undec-7-ene (DBU, 
0.182 g, 1.2 mmol) stir 10 min in DCM. Compound 6 was added to above solution 
and stirred 2 more hours. After reaction is finish. Remove solvent, purify on silica 
gel. Yield: 80 %. 1H NMR (CDCl3, 300 MHz): 8.48-8.45 (dd, J = 7.8 Hz, 1H), 8.28 
(s, 1H), 8.26-8.23 (d, J = 9.0 Hz, 1H), 8.06-8.03 (d, J= 7.8, Hz, 1H), 7.74-7.71 (d, 
J= 9.0 Hz, 1H), 7.37-7.36 (d, J= 2.7 Hz, 1H), 7.24-7.20 (dd, J= 9.2, 2.9 Hz, 1H), 
6.72-6.69 (dd, J= 9.0, 5.4 Hz, 1H), 6.52 (d, J= 2.1 Hz, 1H), 6.27 (s, 1H), 5.75 (s, 
2H), 5.35 (s, 2H), 5.00-4.99 (d, J= 2.4 Hz, 2H), 3.66-3.64 (t, J= 4.5 Hz, 1H), 3.46-
3.40 (q, J= 20.1 Hz, 4H), 1.15-1.10 (t, J= 13.8 Hz, 6H). 13C NMR (CDCl3, 75 MHz): 
163.70, 162.00, 161.32, 160.55, 156.00, 148.15, 140.58, 135.71, 134.61, 134.09, 
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132.53, 129.22, 127.86, 126.22, 123.94, 123.22, 115.31, 114.48, 108.71, 105.90, 
79.24, 78.09, 75.17, 64.10, 56.35, 43.98, 12.29. TOF-HRMS (m/z) found (calcd.) 
for C33H27N3O10 (M): [M+H]+, 626.1782 (626.1775). 
Compound 8 
Tris[(1-benzyl-1H-1,2,3-triazol-4-yl) methyl] amine (50 nmol), Copper (I) iodide (50 
nmol), and Sodium Ascorbate (VcNa) (100 nmol) were mixed together in DMSO. 
Followed by Morpholinos (50 nmol) in water, small molecule (100 nmol) in DMSO. 
The mixture was shacked and incubated 15h. Separate on HPLC. 
8c: MS (modify protein way) (m/z) found (calcd.): 5338.4. (5336.1).  
Compound 9 
Tris[(1-benzyl-1H-1,2,3-triazol-4-yl) methyl] amine (50 nmol), Copper (I) iodide (50 
nmol), and Sodium Ascorbate (VcNa) (100 nmol) were mixed together in DMSO. 
Followed by Morpholinos (50 nmol) in water, small molecule (100 nmol) in DMSO. 
The mixture was shacked and incubated 15h. Separate on HPLC. 
MS (modify protein way) (m/z) found (calcd.): 3995.6 (3996.1). 
Bifunctional molecule with fluorophore mimic 
Compound 3 was synthesized as described below, 
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5-Hexynoic acid (112 mg, 1 mmol), N-(3-Dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride (EDC, 230 mg, 1.2 mmol), and Et3N (202 mg, 2 
mmol) were stirred in DCM 30min. Then Compound 2 (374 mg, 1.2 mmol) was 
added to above solution. Stir overnight at room temperature. Purify on silica gel. 
Rf= 0.4 (Ethyl acetate). Yield: 84 %. 1H NMR (CDCl3, 300 MHz): 8.55-8.53 (dd, J 
= 7.5, 0.9 Hz, 1H), 8.39-8.36 (d, J= 8.4 Hz, 1H), 8.22-8.19 (dd, J= 8.4, 0.9 Hz, 1H), 
7.64-7.59 (d, J = 15.6 Hz, 1H), 7.12 (s, 1H), 6.50-6.47 (m, 2H), 4.17-4.11 (t, J= 
15.0 Hz, 2H), 3.79-3.73 (m, 2H), 3.45-3.42 (m, 2H), 2.47-2.42 (t, J= 14.7 Hz, 2H), 
2.26-2.21 (m, 2H), 1.94-1.88 (m, 2H), 1.72-1.69 (m, 2H), 1.47-1.39 (m, 2H), 0.98-
0.93 (t, J= 14.7 Hz, 2H). 13C NMR (CDCl3, 75 MHz): 175.68, 164.77, 164.32, 
150.00, 134.41, 131.13, 129.75, 124.94, 122.83, 120.33, 109.95, 103.21, 83.10, 
69.47, 46.55, 39.96, 38.97, 34.87, 30.35, 24.08, 20.45, 17.77, 13.89. TOF-HRMS 
(m/z) found (calcd.) for C24H27N3O3 (M): [M+H]+, 406.2129 (406.2131). 
Compound 4 
Tris[(1-benzyl-1H-1,2,3-triazol-4-yl) methyl]amine (50 nmol), Copper (I) iodide (50 
nmol), and Sodium Ascorbate (VcNa) (100 nmol) were mixed together in DMSO. 
Followed by Morpholinos (50 nmol) in water, small molecule (100 nmol) in DMSO. 
The mixture was shacked and incubated 15h. Separate on HPLC. 
4b: MS (modify protein way) (m/z) found (calcd.): 4529.9 (4529.1). 14MO- NXYA 
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Pull down assay 
We purchased 3’-biotin-labeled 14-mer and 3’-biotin-labelled 25-mer MOs for pre-
miR-21 from Gene-Tools. Total RNAs purified (using Oligotex mRNAs kit from 
QIAGEN, Hilden, Germany) from HeLa cells (known to express miR-21) at 37°C. 
125 µl of streptavidin beads was taken and washed with washing buffer (10mM 
MgCl2, 50mM Tris HCl pH 7.8, 150 mM KCl, 10% Glycerol, 0.1% NP40) twice. 
These beads were divided into three equal parts in three 0.5 ml tubes, mixed with 
45.4 ul of incubation buffer (10mM MgCl2, 50mM Tris HCl pH 7.8, 150 mM KCl, 
10% Glycerol, 0.1% NP40 and 1U/µl RNase inhibitor) and incubated for 15 minutes 
at room temperature. To the first and second tubes, each of the 12 µl of 14MO-
biotin (100 µM) and 25-MO-biotin (100 µM) were added respectively and to the 
third tube 12 µl of Biotin only (100 µM) was added. Each tube was incubated with 
1/3rd of total RNAs at 37°C for two hours by shaking. Each sample was transferred 
to 1.5 ml tube, spinned down and removed supernatant liquid. The beads were 
washed three times with 1ml of washing buffer incubating for 5 minutes in each 
step at room temperature. Then each tube was washed with 1ml nuclease-free 
water before adding 500 µl of 3M Urea and incubate at room temperature with 
shaking for one hour. Each sample was centrifugated and taken out the 
supernatant (pull downed RNA) carefully and performed ethanol precipitation to 
recover total RNA pull downed by each sample.   
Alpha-P-32 labelling of pre-miR-21/29b1  
The sequence of hsa-pre-miR-21 was obtained from miRbase 
(http://www.mirbase.org/). The hsa-pre-miR-21 RNA was in-vitro transcribed from 
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template DNA with T7-promoter. DNA template for in-vitro transcription was made 
from following primers, 
Briefly, forward primer with T7 promoter 
5’-
GAAATTAATACGACTCACTATAGGTGTCGGGTAGCTTATCAGACTGATGTTG
ACTGTTGAATCTCATGGC-3’  
And reverse primer 
5’-TGTCAGACAGCCCATCGACTGGTGTTGCCATGAGATTCAACAGTCAAC-3’  
Similarly, for hsa-pre-miR-29b1 
Forward primer with T7 promoter 
5’-
GAAATTAATACGACTCACTATAGGCTTCAGGAAGCTGGTTTCATATGGTGGT
TTAGATTTAAATAGTGATTGTCTA-3’ 
And reverse primer 
5’-
CCCCCAAGAACACTGATTTCAAATGGTGCTAGACAATCACTATTTAAATCT-3’ 
0.8 μM each, were subjected to primer extension using Taq polymerase (5 U), 
dNTPs (0.2 mM), Taq polymerase buffer (10X) and MgCl2 (1 mM). The reaction 
mixture was denatured by heating at 95° C for 30 seconds followed by annealing 
at 55°-58° C for 1 minute and primer extension incubation at 68° C for 1 minutes. 
This cycle was repeated 30 times before going to final extension at 68° C for 5 
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minutes. The hybrid template with T7 promoter was checked using Agrose gel and 
used for in vitro transcription with alpha-P32-UTP following manufacturer’s 
instructions (Ambion Inc.). The pre-miR-21 substrate was purified by NucAway 
Spin Columns (Ambion Inc.) and checked on 16 % denaturing PAGE. 
Dicer cleavage inhibition assay 
32P-labeled pre-miRNA was prepared as described earlier. A 10 µL of the reaction 
mixture was made by incubating 32P-labeled pre-miR-155 (1 µL, ~20 ng) with Dicer 
enzyme (Gen-Lantis) (1 µL) and various concentrations of compounds in buffer 
(HEPES 24 mM, NaCl 200 mM, EDTA 0.04 mM, MgCl2 2.5 mM, ATP 1 mM, pH 
7.5) at 37 °C for 2.5 h. The reaction was stopped by boiling with equal volume of 
Gel Loading Buffer II (Thermo-Fisher Scientific) for 5 min. The non-cleaved pre-
miRNA and the processed miRNA were resolved by 18% denaturing 
polyacrylamide gel. The gel was imaged with phosphor imager and analyzed by 
quantity one software (Bio-Rad). 
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Chapter 3 
Optimization of bi-functional regulators and cellular delivery 
3.1 Introduction 
After showing bi-functional strategy works, we next focused on optimizing each 
functional unit of our bi-functional molecules and the cellular delivery. We tested 
the effects of additional Dicer inhibition molecules and other ASOs as well as 
testing attaching the cell penetrating peptide (CPP) to facilitate the delivery. 
3.2 Results and discussions 
Optimization of the inhibition unit  
Although the N-hydroxyl phthalimide (compound 1) worked as the Dicer inhibition 
unit in our bi-functional regulator, we expected that other more potent RNase III 
inhibitors (e.g. N-hydroxyimides, diketobutanoates or Flutimides, 4, 5 and 6) may 
enhance the activity of bi-functional regulators.1-6 To test this, we synthesized 
compound 20 containing a more potent inhibitor and a short linker and conjugated 
it to the 12-mer and 14-mer MOs designed for pre-miR-21 to give new bi-functional 
regulators (compound 21 and 22) (Scheme 3.1). 
Scheme 3.1: Synthesis of bi-functional molecule with more potent inhibitor 
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Another strategy to enhance the activity of the Dicer inhibition unit is based on the 
crystal structure of Dicer with a double-stranded RNA, which shows two different 
cutting sites separated by 17.5 A°, involved in the cleavage of two RNA strands1 
(Figure 3.1).  We postulated that a Dicer inhibition unit with two inhibitors can 
inhibit both the active sites simultaneously giving more potent inhibition. We 
designed and synthesized new Dicer inhibition units containing two compounds 1 
with different linker lengths (compounds 23 and 24 in Scheme 3.2 and 3.3) and 
then tested their Dicer inhibition activity.  
 
 
 
 
Figure 3.1: Crystal structure of Giardia Dicer. (A) Front and side view of Dicer showing 
the N-terminal platform domain (blue), the PAZ domain (orange), the connector helix 
(red), the RNase IIIa domain (yellow), the RNase IIIb domain (green)1 
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Scheme 3.2: Synthesis of two head inhibitor bi-functional regulator with short linker 
lengths 
Scheme 3.3: Synthesis of two head inhibitor bi-functional regulator with long linker 
lengths 
67 
 
Dicer inhibition assay of optimized inhibitor modules and bifunctional 
molecules  
We compared the activity of new Dicer inhibition units we synthesized with the 
previously used compound 7 by the Dicer cleavage assay. All the new inhibitors 
showed enhanced activity as compared to compound 7. The new inhibitor unit with 
N-hydroxy imides (compound 20) shows at least four times better activity as 
compared to compound 7 and compound 24 with two units of compound 7 
connected by a longer linker shows at least 10 times improved activity (Figure 
3.2).  
Figure 3.2: Dicer cleavage assay for optimized inhibition modules A) and B) Gel 
electrophoresis of cleaved and un-cleaved pre-miR-21 C) and D) quantification of pre-miR-21 band 
in each lane (3-independent experiments were used to calculate the error bar) for A and B 
respectively  
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We next tested the activity of bi-functional molecules, compounds 21 and 22, which 
contain N-hydroxy imide (compound 20) as the Dicer inhibition unit and compared 
to the original bi-functional molecule (compound 12) using the Dicer cleavage 
assay. Unexpectedly, we didn’t observe any enhanced activity from new bi-
functional regulator with more potent inhibitor unit (Figure 3.3). Furthermore, from 
compound 22 and 21 with 14-mer and 12-mer MO respectively also showed similar 
activity. In addition, we synthesized bi-functional molecules incorporating 
compound 23 and 24 as the inhibition units and tested their activity, which 
Figure 3.3:  Dicer cleavage assay for optimized bifunctional molecules A) and B) Gel 
electrophoresis of cleaved and un-cleaved pre-miR-21 C) and D) quantification of pre-miR-21 band 
in each lane (3-independent experiments were used to calculate the error bar) for A and B 
respectively  
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unfortunately did not show any inhibition. Overall, our attempts to improve the 
activity of bi-functional molecules by enhancing the activity of Dicer inhibition unit 
have not been successful.  
Effect of the presence of other RNAs on regulator activity 
In the cellular environment, many other RNA species exist that may also bind the 
bi-functional regulators due to the imperfect pairing with the MOs used in the bi-
functional molecule. This may lead to a reduced activity in cells as we observed 
than reflected in the Dicer cleavage assay performed previously, which only 
contain the pre-miR-21. To find out whether the presence of other RNAs as in cells 
diminishes the activity of our bifunctional molecules, Dicer cleavage assays were 
carried out in absence and presence of equivalent total RNA. We observed that 
the presence of total RNA has almost no effect on the potency of our bi-functional 
molecule on the processing of pre-miR-21 (Figure 3.4), which indicates that the 
lack of cellular activity observed previously is likely not due to this possibility. 
Figure 3.4:  Dicer cleavage assay for bi-functional molecules in presence of total RNA 
A) Gel electrophoresis of cleaved and un-cleaved pre-miR-21 B) quantification of pre-miR-21 
band in each lane (3-independent experiments were used to calculate the error bar) for A 
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Optimization of recognition module 
Since the optimization on the Dicer inhibition units did not offer increased activity 
of the bi-functional molecules, we next focused on the change of the pre-miRNA 
recognition unit. Peptide Nucleic Acids (PNAs), are ASOs with phosphodiester 
backbone replaced by N-(2-aminoethyl) glycine units. PNAs have high binding 
affinity, are resistant towards enzymatic degradation and easier to synthesize. 
However, their neutral backbone cause decreased aqueous solubility.7-20  
 
Our collaborator, Prof. Danith Ly at Carnegie Mellon University has developed a 
new class of PNAs incorporating conformationally preorganized, diethylene glycol-
containing γPNAs which shows enhanced binding affinity with DNA/RNA and water  
 
Figure 3.5: Chemical Structures of DNA (RNA), PNA, and MP-Containing γPNA Units20 
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solubility (Figure 3.5 and 3.6).20-22 To test if yPNAs would serve as better 
recognition units, we designed 7-nt (FL1), 9-nt (FL2) and 11-nt (FL3) yPNA 
oligonucleotides with 3’-azide modification to target the loop region of pre-miR-21. 
FL4 (11-mer) was designed as a negative control that cannot recognize pre-miR-
21. 
y-PNA  
FL1                     ACAACTT 
FL2                     ACAACTTAG 
FL3                     ACAACTTAGAG 
Figure 3.6:  Synthesis of R-MPγPNA Monomers20 
72 
 
FL4                     ACTCCATCATCC (negative control) 
To find out if these γPNAs bind pre-miR-21, gel shift assays were performed. We  
 
Figure 3.8:  Dicer cleavage assay for γPNAs A) Gel electrophoresis of cleaved and un-cleaved 
pre-miR-21 and pre-miR-29b1 B) quantification of pre-miR-21 (lane 1-6) and pre-miR-29b1 (lane7-
12) band in each lane (3-independent experiments were used to calculate the error bar) for A  
A 
B 
Figure 3.7: Gel Shift assays for γPNA oligonucleotides 
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incubated P32 labelled pre-miR-21 with each γPNA oligonucleotide for 1 h and 
analyzed by 15% nondenaturing polyacrylamide gel followed by exposing to 
photographic screen and detected using BioRad PMI. Only FL2 (9-mer) and FL3 
(11-mer) were found to be able to bind pre-miR-21, whereas the shorter γPNA 
oligonucleotide (FL1, 7-mer) and negative control show no binding affinity (Figure 
3.7). The Dicer cleavage assays were then performed to determine the inhibitory 
activity of γPNAs. We observed that both FL2 and FL3 show certain activity 
especially the longer γPNA (FL3) and such inhibition is specific to miR-21 (Figure 
3.8). We coupled FL3 N-hydroxy imide (compound 18) using click chemistry to give 
a bi-functional molecule FL3-6-R (compound 25). Dicer cleavage inhibition assay 
was then carried out with γPNA (FL3) alone or the bi-functional molecule 
(compound 25). We observed that the bi-functional molecule indeed has increased 
activity than individual units (Figure 3.9).  
 
Figure 3.9:  Dicer cleavage assay for γPNA-bifunctional molecule A) Gel electrophoresis 
of cleaved and un-cleaved pre-miR-21 B) quantification of pre-miR-21 band in each lane (3-
independent experiments were used to calculate the error bar) for A  
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Comparative inhibition potency of bi-functional molecules 
To compare if the bi-functional regulator with yPNA has increased activity than 
MO, we calculated the half inhibitory concentration (IC50) of compound 12 (with 
N-hydroxy phthalimide inhibitor and 14-me MO), compound 22 (with N-hydroxy 
imide and 14-mer MO) and compound 25 (with N-hydroxy imide and yPNA). 
Dosage dependent Dicer cleavage assays were carried out for each molecule from 
low to high concentrations under similar experimental condition and IC50 value 
was obtained for each bifunctional molecule. 
 
Figure 3.10: IC50 value of three most potent bi-functional molecules (three independent 
Dicer cleavage inhibition assays were carried out with series dilution for each molecule to 
calculate errors) 
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IC50 values for compounds 12,22 and 25 were found to be 4.2 µM, 3.5 µM and 
0.5 µM (Figure 3.10). From these results, we found that optimizing the pre-miRNA 
recognition unit can potentially offer a way to improve the activity of the bi-
functional regulators. 
Using CPPs to facilitate the cellular delivery of bi-functional molecules  
Since Endo-porter had failed to efficiently deliver the bi-functional regulators, we 
explored the possibility of incorporating CPPs (oligopeptides typically less than 30 
aa residues and net positive charge) to enhance cellular delivery (Table 3.1).23-28  
CPP-mediated transport system has been used successfully to deliver cargos (e.g. 
ASOs, siRNAs, antibodies, proteins) into the cells (Figure 3.11).27 
 
Figure 3.11: CPP-conjugated molecule delivery across the cell membrane27 
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We chose to incorporate the commonly used polyarginine (R8) peptide (Figure 
3.12) to deliver our bi-functional molecule. To test if R8 can be used to deliver MO, 
we synthesized a fluorescently labeled model bi-functional molecule incorporating 
a cysteine (Cys)-conjugated CPP in bifunctional molecule through a disulfide bond 
(compound 26, Scheme 3.4). Under the reducing environment in cells, it is 
expected that the disulfide bond will be cleaved to give free bifunctional 
regulator.29,30 
Name Sequence Length Charge 
Penetratin RQIKIWFQNRRMKWKK 16 7(+) 
TAT GRKKRRQRRRPPQ 13 8(+) 
Transportin GWTLNSAGYLLGKINLKALAALAKKIL 27 5(+) 
R9 peptide RRRRRRRRR 9 9(+) 
MPG peptide GALFLGWLGAAGSTMGAPKKKRKV 24 5(+) 
KALA peptide WEAKLAKALAKALAKHLAKALAKALKACEA 30 7(+) 
 
Table 3.1: Most commonly used CPPs23-28  
Figure 3.12: CPP (R8) used to deliver bi-functional mimic 
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We examined the cellular delivery of molecule 26 in Hela cells and found that R8 
CPP significantly increased the delivery efficiency as compared to the delivery by 
Endo-porter (Figure 3.13). 
Scheme 3.4: Synthesis of CPP-conjugated fluorophore bi-functional mimic 
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Synthesis of CPP-conjugated bifunctional molecule was attempted by 
incorporating 3’-azide as well as protected sulfohydryl group at 5’-end in 
Morpholino recognition module, but several synthetic problems have been 
encountered, including the low purity of modified Morpholino from Gene-Tools. 
 
 
 
Figure 3.13: Comparison between cellular delivery by CPP-conjugated system vs Endo-
porter A) Delivery of molecule by CPP-conjugation at different concentration B) Delivery of 
molecule without conjugating CPP and using Endo-porter (all the images were taken after 
washing out media) 
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3.3 Conclusion  
In this chapter, we investigated different strategies to optimize our bifunctional 
regulators. We found that incorporating more potent inhibition units did not 
increase the potency of bi-functional molecules significantly. One potential reason 
may be that since, bifunctional design specifically enriches the Dicer inhibitor unit 
at the active site of Dicer associated with targeted miRNAs, the local concentration 
of inhibitor might be already very high that even a less potent inhibitor can be 
sufficient to inhibit Dicer activity. 
However, our attempts to employ a more potent ASO as the pre-miRNA 
recognition unit did lead to a more potent bi-functional molecule. We switched MOs 
to PNA as the recognition unit and were able to decrease their lengths from 14-
mer in MO to 11-mer in PNA. The resulting PNA-based bi-functional molecule 25 
has shown at least 7-fold increase in potency as compared to other MO-based 
bifunctional molecules (compounds 12 and 22). 
Finally, we showed that R8 CPP can efficiently deliver a model MO-based bi-
functional probe, which can be used for future delivery of the bifunctional regulators 
into the cells.  
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3.4 Methods  
Optimized inhibition modules synthesis 
Compound 1 
To a stirred solution of 2-(carboxymethyl)-5-hydroxybenzoic acid (1.00 g) in MeOH 
(50 mL) was added sulfuric acid (200 μL) dropwise. The mixture was refluxed for 
4 h. The solvents were removed by vacuum and the residue was partitioned 
between water (50 mL) and ethyl acetate (50 mL). The organic phase was washed 
with water (2 X 50 mL) and dried over Na2SO4. The solid was removed by filtration. 
The filtrate was vacuumed to remove the solvent. The crude product was purified 
by chromatography (Hexane/Ethyl Acetate: 1/1) to give 1 as a yellow oil (0.98 g, 
86%). 1 H NMR (300 MHz, DMSO): δ (ppm) 9.76 (s, 1H), 7.31 (d, J = 2.7 Hz, 1H), 
7.16 (d, J = 8.4 Hz, 1H), 6.92 (dd, J = 8.4 Hz, 2.7 Hz, 1H), 3.84 (s, 2H), 3.75 (s, 
3H), 3.57 (s, 3H).  
Compound 2 
To a stirred solution of 1 (200 mg, 0.89 mmol) in DMF (5 mL) was added K2CO3 
(370 mg) and propargyl bromide (400 mg, 80% in toluene, 2.68 mmol). The 
reaction was stirred overnight at 70 o C. Water (50 mL) was added. The mixture 
was extracted with ethyl acetate (2 X 50 mL). The combined organic phase was 
washed with brine (3 X 50 mL) and dried over Na2SO4. The solid was filtered off. 
81 
 
The filtrate was vacuumed to remove the solvent. The residue was further purified 
by chromatography (Hexane/Ethyl Acetate: 5/1) to give 2 as a yellow oil (0.195 g, 
yield 83%). 1 H NMR (300 MHz, MeOD): δ (ppm) 7.59 (d, J = 2.7 Hz, 1H), 7.24 (d, 
J = 8.4 Hz, 1H), 7.15 (dd, J = 8.4 Hz, 2.7 Hz, 1H), 4.77 (d, J = 2.4 Hz, 2H), 3.94 (s, 
2H), 3.84 (s, 3H), 3.66 (s, 3H), 2.97 (t, J = 2.4 Hz, 1H). 13 C NMR (300 MHz, 
MeOD): δ (ppm) 174.2, 168.6, 158.1, 134.6, 131.8, 130.1, 120.0, 118.1, 79.4, 77.2, 
56.8, 52.5, 52.3, 40.3. HRMS (ESI) m/z [M + Na]+ 285.0731, calculated for 
C14H14O5Na 285.0739 
Compound 3 
To a solution of 2 (1 eq) in methanol (5 mL) was added water (5 mL) and LiOH·H2O 
(4 eq). The reaction was stirred overnight at room temperature. The solvents were 
removed by vacuum. The residue was dissolved in water (10 mL). Concentrated 
HCl (2 mL) was added to adjust the pH to 1, resulting in white precipitation. The 
solid was collected by filtration and dried to give the product as a white solid. 290 
mg of 2 was used to produce 187 mg of3 (white solid, yield 72%). 1 H NMR (300 
MHz, MeOD): δ (ppm) 7.63 (d, J = 2.7 Hz, 1H), 7.23 (d, J = 8.4 Hz, 1H), 7.14 (dd, 
J = 8.4 Hz, 3.0 Hz, 1H), 4.77 (d, J = 2.4 Hz, 2H), 3.95 (s, 2H), 2.96 (t, J = 2.4 Hz, 
1H). 13 C NMR (75 MHz, MeOD): δ (ppm) 175.8, 170.0, 157.9, 134.5, 132.4, 
130.7, 119.8, 118.4, 79.5, 77.1, 56.8, 40.4. HRMS (ESI) m/z [M + H]+ 233.0451, 
calculated for C12H9O5 233.0450. 
Compound 4 
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A solution of 3 (1 eq) and O-(4-Methoxybenzyl)-hydroxylamine (1.2 eq) in toluene 
(180 mL) was refluxed using a Dean-Stark apparatus overnight. The solvent was 
removed by vacuum and the residue was purified by column chromatography. 
Compound 3 (187 mg) was used to give 4 (174 mg) as a white solid. Elution 
solvent: Hexane/Ethyl acetate 2/1; yield 62%. 1 H NMR (300 MHz, CDCl3): δ 
(ppm) 7.76 (d, J = 2.1 Hz, 1H), 7.52 (d, J = 8.7 Hz, 2H), 7.22 (m, 2H), 6.90 (d, J = 
8.7 Hz, 2H), 5.08 (s, 2H), 4.77 (d, J = 2.1 Hz, 2H), 4.07 (s, 2H), 3.81 (s, 3H), 2.56 
(t, J = 2.4 Hz, 1H). 13 C NMR (75 MHz, CDCl3): δ (ppm) 166.0, 161.5, 160.4, 
157.2, 131.8, 128.9, 126.4, 126.2, 122.9, 114.0, 112.8, 78.1, 77.8, 76.4, 56.3, 55.4, 
37.0. HRMS (ESI) m/z [M + Na]+ 374.1008, calculated for C20H17NNaO5 
374.1004.  
Compound 5 
To a stirred solution of 4 (27 mg, 0.077 mmol) in DCM (1.5 mL) was added TFA 
(1.5 mL). The reaction turned to dark red after 4 h. The solvents were removed by 
vacuum. The residue was washed with ether (3 X 1.5 mL) to give 5 as a white solid 
(15 mg, yield 81%). 1 H NMR (300 MHz, DMSO): δ (ppm) 10.39 (s, 1H), 7.57 (d, 
J = 2.4 Hz, 1H), 7.31 (m, 2H), 4.90 (d, J = 2.1 Hz, 2H), 4.18 (s, 2H), 3.60 (t, J = 2.1 
Hz, 1H). 13 C NMR (75 MHz, DMSO): δ (ppm) 166.4, 161.5, 156.2, 129.1, 127.5, 
126.0, 121.7, 111.9, 78.8, 78.7, 55.7, 36.2. HRMS (ESI) m/z [M + H]+ 232.0616, 
calculated for C12H10NO4 232.0610 
Compound 6 
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Tris[(1-benzyl-1H-1,2,3-triazol-4-yl) methyl] amine (50 nmol), Copper (I) iodide (50 
nmol), and Sodium Ascorbate (VcNa) (100 nmol) were mixed together in DMSO. 
Followed by Morpholinos (50 nmol) in water, small molecule 5 (100 nmol) in 
DMSO. The mixture was shacked and incubated 15h. Separate on HPLC. 
6a (with 12 MO-21) = MS (modify protein way) (m/z) found (calcd.): 4516.34 
(4516.21).  
6b (with 14 MO-21) = MS (modify protein way) (m/z) found (calcd.): 5170.64 
(5171.21).  
Synthesis of FL3 bi-functional molecule 
Tris[(1-benzyl-1H-1,2,3-triazol-4-yl) methyl] amine (50 nmol), Copper (I) iodide (50 
nmol), and Sodium Ascorbate (VcNa) (100 nmol) were mixed together in DMSO, 
followed by FL3 (50 nmol) in water, small molecule 5 (100 nmol) in DMSO. The 
mixture was shacked and incubated 5h, Separated on HPLC to get FL3-6R 
bifunctional molecule. MS = m/z found (calcd.) 4695.01 (4696.57) 
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Compound 2 
To a stirred solution of dimethyl 5-hydroxyisophthalate (DMHIP, 6.3 g, 30 mmol) 
and propargyl bromide (80% in toluene, 5.0 g, 33 mmol) in DMF (100 mL) were 
added potassium carbonate (4.2 g, 30 mmol). The reaction mixture was stirred at 
90℃ about 2h. After the reaction finished, extract with Ethyl acetate/brine. 
Combine organic solvent, dry with Na2SO4. Remove the solvent, White solid was 
obtained. 1H NMR (CDCl3, 300 MHz): 8.33-8.32 (t, J= 3.0 Hz, 1H), 7.83-7.82 (d, 
J = 1.5 Hz, 2H), 4.79-4.78 (d, J= 2.4 Hz, 2H), 3.94 (s, 6H), 2.56-2.54 (t, J= 4.5 Hz, 
1H).  
Compound 3 
LiAlH4 (1.6 g, 42 mmol) and THF (40 mL) was added in a 250-ml flask, the mixture 
was kept in ice bath and stirred for 10 min. DMPIP (4.5 g, 20 mmol) in THF (60 
mL) was dropped into the flask. The reaction stood in ice bath for 1 h, then at room 
temperature for 7 h. After that, the reaction was quenched with water, and the 
mixture was filtrated and dried with anhydrous MgSO4. After the removal of solvent 
by rotary evaporation, the crude product was crystallized in hexane to give 1,3-
dihydromethyl-5-proparyloxybenzene (DHMPB) as white crystals. 1H NMR 
(Acetone-d6, 500 MHz): 6.96 (s, 1H), 6.89 (s, 2H), 4.76 (d, J = 2.0 Hz, 2H), 4.60-
4.59 (d, J= 5.5 Hz, 4H), 4.32-4.30 (t, J= 10.1 Hz, 2H), 3.05 (s, 1H). TOF-HRMS 
(m/z) found (calcd.) for C11H12O3 (M): [M+Na]+, 215.0674 (215.0684). 
Compound 4 was made following the routine methods. 
Compound 5 
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1H NMR (DMSO-d6, 500 MHz): 11.02 (s, 2H), 8.40-8.38 (d, J= 8.4 Hz, 2H), 8.21 
(s, 2H), 7.97-7.96 (d, J = 7.5 Hz, 2H), 7.25 (s, 1H), 7.15 (s, 2H), 5.40 (s, 4H), 4.85 
(s, 2H), 3.56 (s, 1H). 13C NMR (CDCl3, 75 MHz): 175.68, 164.77, 164.32, 150.00, 
134.41, 131.13, 129.75. TOF-HRMS (m/z) found (calcd.) for C29H18N2O11 (M): 
[M+H]+, 571.1009 (571.0989); [M+Na]+, 593.0830 (593.0808). 
Compound 6 
Tris[(1-benzyl-1H-1,2,3-triazol-4-yl) methyl] amine (50 nmol), Copper (I) iodide (50 
nmol), and VcNa (100 nmol) were mixed together in DMSO. Followed by 
Morpholinos (50 nmol) in water, small molecule (100 nmol) in DMSO. The mixture 
was shacked and incubated 15h. Separate on HPLC. 
MS (modify protein way) (m/z) found (calcd.): 5510.8 (5510.1). 14MO-DI-PA 
 
Compound 2 
Into a solution of 1 in THF (10 ml), SOCl2 and DMF were added. The reaction was 
refluxed for 2 h. The solvent was removed by vacuum and residue was dissolved 
in THF (5 ml) and the THF was removed by vacuum to get compound 2. 
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Compound 4 
Into a solution of 3 in DCM (5 ml), TEA was added. The reaction was cooled to 
0°C. A solution of 2 in DCM (5 ml) was then added dropwise. The reaction was 
allowed for warming to room temperature and stirred for overnight. The reaction 
was washed with H2O (1x10 ml) and dried over Na2So4. The solvent was removed 
by vacuum. The residue was purified by chromatography (Hexane: EA=3:1) to give 
the product 4 as a white solid (81%). 
Compound 5 
Into a solution of 4 in DCM, TFA was added. The reaction was stirred for 3 h. the 
solvent was removed by vacuum. CH3CN (5 ml) was added to the residue and then 
removed by vacuum. It was repeated for 4 times and the residue was then titrated 
with Et2O to form white solid. It was collected by filtration and dried over vacuum 
to give the product as a white solid (100%). 1H NMR (300 MHz, D2O, δ) 8.22 (m, 
1H), 8.12 (d, J = 7.5 Hz, 1H), 7.11 (m, 1H), 7.30 (m, 5H), 5.03 (s, 2H), 4.33 (br, 
2H), 3.07 (t, J = 7.2 Hz, 2H), 2.07 (m, 2H). HRMS (ESI) m/z [M+H]+= 355.1290 
(M+1)+ 
Compound 7 
Same as in compound 2 
Compound 8 
Into a solution of 5 and 7 in DCM, TFA was added at 0°C. The reaction was stirred 
for 12 h. Then the reaction was diluted with DCM (10 ml) and washed with water 
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(3X 10 ml). the organic phase was purified by chromatography (MeOH: 
DCM=1:30) to give the product 8 (76%).1H NMR (300 MHz, CDCl3, δ) 8.32 (m, 
4H), 7.77 (m, 3H), 7.50 (m, 6H), 7.36 (m, 6H), 7.10 (t, J = 5.7 Hz, 2H), 5.21 (s, 4H), 
4.69 (d, J = 2.1 Hz, 2H), 4.46 (t, J = 5.7 Hz, 4H), 3.58 (q, J = 6.0 Hz, 4H), 2.57 (t, 
J = 2.1 Hz, 1H), 2.10 (t, J = 6.0 Hz, 4H). HRMS (ESI) m/z [M+H]+ = 893.2669 
(M+1)+ 
Compound 9 
Compound 8 was dissolved in CH3SO3H and stirred for 2 h at room temperature. 
5ml of water was added to the reaction, and white solid was obtained and collected 
by centrifugation and purified by prep-TLC (MeOH: DCM=1:2) to give the product 
as a white solid (46%).1H NMR (300 MHz, DMSO, δ) 11.03 (br, 2H), 8.67 (t, J = 
4.8 Hz, 2H), 8.34 (m, 2H), 8.19 (t, J = 0.6 Hz, 2H), 7.92 (m, 3H), 7.53 (d, J = 1.2 
Hz, 2H), 4.86 (d, J = 2.4 Hz, 2H), 4.39 (t, J = 6.0 Hz, 4H), 3.60 (s, 1H), 3.58 (m, 
4H), 2.00 (q, J = 6.0 Hz, 4H). HRMS (ESI) m/z [M+H]+ = 713.1750 (M+1)+ 
Alpha-P32-UTP labelling of pre-miR-21/29b1 
The sequence of hsa-pre-miR-21 was obtained from miRbase 
(http://www.mirbase.org/). The hsa-pre-miR-21 RNA was in-vitro transcribed from 
template DNA with T7-promoter. DNA template for in-vitro transcription was made 
from following primers, 
Briefly, forward primer with T7 promoter 
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5’-
GAAATTAATACGACTCACTATAGGTGTCGGGTAGCTTATCAGACTGATGTTG
ACTGTTGAATCTCATGGC-3’  
And reverse primer 
5’-TGTCAGACAGCCCATCGACTGGTGTTGCCATGAGATTCAACAGTCAAC-3’  
Similarly, for hsa-pre-miR-29b1 
Forward primer with T7 promoter 
5’-
GAAATTAATACGACTCACTATAGGCTTCAGGAAGCTGGTTTCATATGGTGGT
TTAGATTTAAATAGTGATTGTCTA-3’ 
And reverse primer 
5’-
CCCCCAAGAACACTGATTTCAAATGGTGCTAGACAATCACTATTTAAATCT-3’ 
0.8 μM each, were subjected to primer extension using Taq polymerase (5 U), 
dNTPs (0.2 mM), Taq polymerase buffer (10X) and MgCl2 (1 mM). The reaction 
mixture was denatured by heating at 95° C for 30 seconds followed by annealing 
at 55°-58° C for 1 minute and primer extension incubation at 68° C for 1 minutes. 
This cycle was repeated 30 times before going to final extension at 68° C for 5 
minutes. The hybrid template with T7 promoter was checked using Agrose gel and 
used for in vitro transcription with alpha-P32-UTP following manufacturer’s 
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instructions (Ambion Inc.). The pre-miR-21 substrate was purified by Nuc-Away 
Spin Columns (Ambion Inc.) and checked on 16 % denaturing PAGE. 
Dicer cleavage inhibition assay 
32P-labeled pre-miRNA was prepared as described earlier. A 10 µL of the 
reaction mixture was made by incubating 32P-labeled pre-miR-155 (1 µL, ~20 ng) 
with Dicer enzyme (Gen-Lantis) (1 µL) and various concentrations of compounds 
in buffer (HEPES 24 mM, NaCl 200 mM, EDTA 0.04 mM, MgCl2 2.5 mM, ATP 1 
mM, pH 7.5) at 37 °C for 2.5 h. The reaction was stopped by boiling with equal 
volume of Gel Loading Buffer II (Thermo-Fisher Scientific) for 5 min. The non-
cleaved pre-miRNA and the processed miRNA were resolved by 18% denaturing 
polyacrylamide gel. The gel was imaged with phosphor imager and analyzed by 
quantity one software (Bio-Rad). 
CPP-conjugated bifunctional mimic with fluorophore synthesis 
N-Propargyl-4-amido-1,8-naphthalimide (3) was synthesized according literature 
reported procedures*. 
*Chemical Communications (Cambridge, United Kingdom), 52(89), 13086-13089; 
2016 
Compound 1 
2,2’-Dipyridyldisulfide (1.21g, 6.0mmol) was dissolved in MeOH (3ml) and AcOH 
(0.13ml) was added. To this mixture, a solution of 2-mercaptoethanol (0.3ml, 
4.4mmol) in MeOH (3ml) was added dropwise at room temperature over 30 mins 
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period under continuous stirring. The reaction mixture was further stirred at room 
temperature overnight. The solvent was evaporated and residue was purified by 
silica gel column chromatography (EtOAc: Hexane, 1:5 to 1:1), separating the 
product as a colorless oily liquid (0.56g, 68.1% yield). 1H NMR (300 MHz, CDCl3) 
δ ppm 8.502-8.485(m, 1H), 7.616-7.545(m,1H), 7.409-7.375(m, 1H), 7.164-
7.119(m, 1H), 5.753(s, 1H), 3.811(t, 2H, J=4.8Hz), 2.959-2.925(m, 2H). 
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Compound 4:  
To a stirred solution of 3(0.195g, 0.78mmol) and DIPEA (0.300g, 2.3mmol) in dry 
dichloromethane(5ml), a phosgene solution (15 wt. % in toluene, 3.64ml, 5.1mmol) 
was added. The reaction mixture was stirred at 0°C under inert condition. After 2h, 
the excess phosgene was removed from the solution by Argon. Then compound 
1(0.3g, 1.6mmol) in dry dichloromethane(2ml) and DMAP (0.244g, 2.0mmol) was 
added to the reaction mixture and was stirred over-night. After completion of 
reaction (by TLC), the mixture was diluted with EtOAc(10ml), washed twice with 
brine solution, dried over sodium sulfate. Filtered and the residue was purified by 
column chromatography (EtOAc: CH2Cl2 1:10).  Light green solid was purified 
(0.36g, 63.1% yield). 1H NMR (300 MHz, CDCl3) δ ppm 8.705(dd, 2H, J=7.2, 
12.9Hz), 8.470-8.454(m, 1H), 8.389(d, 1H, J= 8.4Hz), 8.287(d, 1H,J= 8.7Hz), 
7.837-7.784(m, 1H), 7.720-7.583(m, 3H), 7.114-7.074(m, 1H), 4.965(d, 2H, 
J=2.4Hz), 4.582(t, 2H, J=6.0Hz), 3.185(t, 2H, J=6.0Hz), 2.200(t, 1H, J=2.4Hz). 
Compound 5  
The compound 4(10ul, 10mM in DMSO) and Morpholino (50ul, 1mM in H2O) were 
mixed together. While stirring the solution, the CuSO4·5H2O/Sodium Ascorbate 
(VcNa) solution (10ul, 10mM aqueous solution) was added. After stirring the 
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mixture at rt for 12 h, the reaction is finished and purified by HPLC to purify the 
product as light-yellow solid.  
MS= (modified protein way) m/z [M+H]+ = 4750 (M+1)+ 
Compound 6  
The compound 5 (50ul, 0.153mM) was mixed with R8 peptide (8ul, 1mM) in tris 
buffer pH 8.0 (50ul, 1M). The solution was stirred at room temperature over-night. 
The mixture was purified by HPLC to give 6 as light yellow solid.  
Fluorescence images of HeLa cells incubated with Compound 6 solution with 
excitation at 359nm, 
MO-FL-R8  
 
 
 
 
 
 
 
 
93 
 
3.5  References 
1. Macrae, I. J. et al. Structural Basis for Double-Stranded RNA Processing by 
Dicer. Science 195, 195–198 (2010). 
2. Klumpp, K. et al. Two-metal ion mechanism of RNA cleavage by HIV RNase 
H and mechanism-based design of selective HIV RNase H inhibitors. 
Nucleic Acids Res. 31, 6852–6859 (2003). 
3. Sun, W., Pertzev, A. & Nicholson, A. W. Catalytic mechanism of Escherichia 
coli ribonuclease III: kinetic and inhibitor evidence for the involvement of two 
magnesium ions in RNA phosphodiester hydrolysis. Nucleic acids research 
33, 807-815, (2005). 
4. Cianci, C. et al. Identification of N-hydroxamic acid and N-hydroxy-imide 
compounds that inhibit the influenza virus polymerase. Antivir. Chem. 
Chemother. 7, 353–360 (1996). 
5. Parkes, K. E. B. & Ermert, P. Use of a pharmacophore model to Discover a 
new class of Influenza Endonclease inhibitors. 1153–1164 (2003). 
6. Kolb, H. C., Finn, M. G. & Sharpless, K. B. Click Chemistry: Diverse 
Chemical Function from a Few Good Reactions. Angew. Chem. Int. Ed. 
Engl. 40, 2004–2021 (2001).  
7. Ray, A. & Norden, B. Peptide nucleic acid (PNA): its medical and 
biotechnical applications and promise for the future. FASEB journal: official 
publication of the Federation of American Societies for Experimental 
Biology 14, 1041-1060 (2000). 
94 
 
8.  Torres, A. G., Threlfall, R. N., & Gait, M. J. Potent and sustained cellular 
inhibition of miR-122 by lysine-derivatized peptide nucleic acids (PNA) and 
phosphorothioate locked nucleic acid (LNA)/2’-O-methyl (OMe) mixmer 
anti-miRs in the absence of transfection agents. Artificial DNA, PNA & 
XNA, 2(3), 71–78 (2011) 
9.  Fabani, M. M., & Gait, M. J. miR-122 targeting with LNA/2′-O-methyl 
oligonucleotide mixmers, peptide nucleic acids (PNA), and PNA–peptide 
conjugates. RNA 14(2), 336–346 (2008) 
10.  Pooga M, Land T, Bartfai T & Langel, U. PNA oligomers as tools for 
specific modulation of gene expression. Biomol. Eng. 17(6),183-92 (2001) 
11.  Boulmé, F., Freund, F., Moreau, S., Nielsen, P. E., Gryaznov, S., Toulmé, 
J. J., & Litvak, S. Modified (PNA, 2’-O-methyl and phosphoramidate) anti-
TAR antisense oligonucleotides as strong and specific inhibitors of in vitro 
HIV-1 reverse transcription. Nucleic Acids Research 26(23), 5492–5500 
(1998). 
12.  Nulf, C. J., & Corey, D. Intracellular inhibition of hepatitis C virus (HCV) 
internal ribosomal entry site (IRES)-dependent translation by peptide 
nucleic acids (PNAs) and locked nucleic acids (LNAs). Nucleic Acids 
Research 32(13), 3792–3798 (2004). 
13.  Donald F. D., Dwaine A. B., Carla G. S., Bethany A. J. & Corey D. R. 
Inhibition of Gene Expression Inside Cells by Peptide Nucleic Acids:  Effect 
of mRNA Target Sequence, Mismatched Bases, and PNA Length. 
Biochemistry 40 (1), 53-64 (2001). 
95 
 
14.  Oh S. Y., Ju Y., Cho H. P. K. W. & Kang Y.  A Highly Effective and Long-
Lasting Inhibition of miRNAs with PNA-Based Antisense 
Oligonucleotides.  Mol. Cells 28,341-345 (2009). 
15. Liu Y., Braasch D. A., Nulf C. & Corey D. R. Efficient and Isoform-Selective 
Inhibition of Cellular Gene Expression by Peptide Nucleic Acids 
Biochemistry 43 (7), 1921-1927 (2004). 
16.  Fabani MM, Abreu-Goodger C, Williams D, et al. Efficient inhibition of miR-
155 function in vivo by peptide nucleic acids. Nucleic Acids Research. 
38(13),4466-4475 (2010) 
17.  Sazani P, Astriab-Fischer A & Kole R. Effects of base modifications on 
antisense properties of 2'-O-methoxyethyl and PNA oligonucleotides. 
Antisense Nucleic Acid Drug Dev. 13(3),119-128 (2003) 
18.  Gupta A., Quijano E., et al. Anti-tumor Activity of miniPEG-γ-Modified 
PNAs to Inhibit MicroRNA-210 for Cancer Therapy. Molecular Therapy -
Nucleic Acids. 9,111-119 (2017). 
19.  Fabbri E., Manicardi A., Tedeschi T. et al. Modulation of the Biological 
Activity of microRNA-210 with Peptide Nucleic Acids (PNAs). 
ChemMedChem 6, 2192 – 2202 (2011) 
20.  Sahu B., Sacui L., Rapireddy S., Ly D. H. et al. Synthesis and 
Characterization of Conformationally Preorganized, (R)-Diethylene Glycol-
Containing γ-Peptide Nucleic Acids with Superior Hybridization Properties 
and Water Solubility. J. Org. Chem. 76 (14), 5614–5627 (2011). 
96 
 
21.  Yeh J. I., Shivachev B., Rapireddy S., Ly D. H. et al. Crystal Structure of 
Chiral γPNA with Complementary DNA Strand: Insights into the Stability 
and Specificity of Recognition and Conformational Preorganization. J. Am. 
Chem. Soc.132, 10717–1072 (2010). 
22.  Wierzbinski E., Leon A. D., Ly D. H., Waldeck D. H. et al. Effect of Backbone 
Flexibility on Charge Transfer Rates in Peptide Nucleic Acid Duplexes. J. 
Am. Chem. Soc. 134, 9335−9342 (2012)   
23.  Krützfeldt, J. et al. Silencing of microRNAs in vivo with ‘antagomirs’. Nature 
438, 685–689 (2005). 
24.  Kabouridis, P. S. Biological applications of protein transduction technology. 
Trends Biotechnol. 21, 498–503 (2003). 
25.  Moulton, H. M., Hase, M. C., Smith, K. M. & Iversen, P. L. HIV Tat peptide 
enhances cellular delivery of antisense morpholino oligomers. Antisense 
Nucleic Acid Drug Dev. 13, 31–43 (2003). 
26.  Veldhoen, S., Laufer, S. D. & Restle, T. Recent developments in peptide-
based nucleic acid delivery. Int. J. Mol. Sci. 9, 1276–1320 (2008). 
27.  Tashima T. Intelligent substance delivery into cells using cell penetrating 
peptides. Bioorg. Med. Chem. Lett. 27(2), 121-130 (2017). 
28.  Juliano R., Alam M. R., Dixit V. & Kang H. Mechanisms and strategies for 
effective delivery of antisense and siRNA oligonucleotides, Nuc. Acid. Res. 
36(12), 4158–4171 (2008). 
29.  Caldarelli, S. A. et al. Disulfide prodrugs of albitiazolium (T3/SAR97276): 
Synthesis and biological activities. J. Med. Chem. 55, 4619–4628 (2012). 
97 
 
30.  Vrudhula, V. M., MacMaster, J. F., Li, Z., Kerr, D. E. & Senter, P. D. 
Reductively activated disulfide prodrugs of paclitaxel. Bioorganic Med. 
Chem. Lett. 12, 3591–3594 (2002). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
98 
 
Chapter 4 
Explore alternative pre-miRNA binder  
4.1 Introduction 
Although ASOs like MOs or PNAs can be used for our bi-functional molecules, 
they have several limitations. To find alternative pre-miRNA binders to be used as 
Figure 4.1:  Biogenesis of miR-155 and downstream cellular function in breast cancer1 
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our recognition unit, we focused on the cyclic peptides, which have been shown to 
recognize RNAs with great cell permeability and stability. In this chapter, we tested 
the activity and selectivity of a novel cyclic peptide scaffold to target miR-155, 
which is a known oncogenic miRNA found to also play roles in cardiovascular 
diseases, immunity disorders, inflammation, and viral infections (Figure 4.1).2-16 
MiR-155 is upregulated in different breast cancer tissues and used as a 
pathological marker, representing tumor condition and survival rate (Table 4.1). It 
has been shown that over expression of miR-155 directly promote tumor formation 
and pharmacological intervention causes tumor regression.1 As a result, miR-155 
becomes an important therapeutic target. 
Table 4.1:  miR-155 expression reported in different breast cancer cell types1 
100 
 
4.2 Results and discussions 
 
Our collaborator, Prof. Jianfeng Cai at University of South Florida, has recently 
developed one-bead−one-compound thioether bridged macrocyclic γ-AApeptide 
combinatorial library containing novel class of the macrocyclic peptidomimetics 
(Figure 4.2). The γ-AApeptides have modified peptide backbone with diverse 
functional side chains to introduce improved protease resistance, chemo-diversity, 
and bioavailability17,18. To explore the possibility of using these peptidomimetics as 
a new class of RNA targeting molecules, we screened the macrocyclic y-
AApeptide library against fluorophore-labelled pre-miR-155. 
 
Figure 4.2: Synthesis of the thioether bridged one-bead−one-compound macrocyclic γ-
AApeptide library17,18 
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Fluorophore labelling of pre-miRNA 
Pre-miR-155 was in-vitro transcribed by using cDNA encoding premiR-155 
sequence with T7 promoter and an extra G-nucleotide at 5’-end. During in vitro 
transcription GMPS (Guanosine mono phosphorothioate) was used along with 
normal ATP, UTP, CTP and GTP in 8:1 ratio19. The in vitro transcribed RNA will  
 
 Figure 4.3: In vitro transcription followed by fluorophore labelling of pre-miRNA 19,20 and 
gel image 
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have free thiol group at its 5’-end through the incorporation of GMPS. We then 
couple the ATTO 488 fluorophore to this free thiol group by reacting with the 
iodoacetamide.20 
To confirm the labeling, fluorophore labelled premiRNA-155 was analyzed by 16% 
polyacrylamide gel electrophoresis to visualize the fluorescence signal. Then 
same gel was also stained with Ethidium Bromide to image RNAs (Figure 4.3). 
The results showed that the pre-miRNA-155 was successfully labelled. 
Identification of pre-miR-155 binder and test its activity 
ATTO-488 labelled pre-miR-155 was screened against a library of macrocyclic 
peptidomimetics by Prof. Cai’s group. From the screening, compound 27 was 
discovered as a hit for pre-miR-155. After the structure was decoded, compound 
27 was resynthesized and subjected to additional assays.  
 
After we validated the binding using the fluorescence polarization assay, the in 
vitro Dicer cleavage assay was carried out to evaluate the activity of compound 
27 (R=H) 
Figure 4.4: Structure of library hit screened against pre-miR-155 
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27. We observed that compound 27 can inhibit the cleavage of pre-miR-155 by 
Dicer at µM concentrations. 
 
Evaluating targeting selectivity by RNAseq 
After we confirmed that compound 27 is active in blocking endogenous miRNA-
155 production (carried out by another lab member), we investigated the targeting 
specificity of this new pre-miR-155 binder by RNAseq and bioinformatics analysis. 
We treated MCF-7 cells with compound 27, a commercial antimiR-155 (from IDT) 
as a positive control. Non-treated cells were used as the negative control and the 
standard for comparison. We performed three replicated experiments for each of 
these three conditions (Table 4.2) and total RNA from each experiment was 
isolated and sent for RNAseq performed by National Center for Genome 
Resources (NCGR). 
 
Figure 4.5: Dicer cleavage assay for macrocyclic peptidomimetics (compound 27) A) 
Gel electrophoresis of cleaved and un-cleaved pre-miR-155 B) quantification of pre-miR-155 
band in each lane (3-independent  experiments were used to calculate the error bar) for A 
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Sample  Condition  Replicates 
A Mcf7 cells only (non-treated) 
 
A1, A2 and A3 
B Mcf7 cells treated with positive control antimiR-155-
5p (IDT) 
 
B1, B2 and B3 
C Mcf7 cells treated with our molecule (Compound 27) C1, C2 and C3 
  
Table 4.2: Description of experimental conditions for RNAseq experiment 
The general process for RNAseq and analysis is illustrated in Figure 4.6 and 4.7. 
we were interested in finding out differential gene expression caused by 
downregulation of miR-155 and by any off-target effect from each treatment. After 
using Illumina sequencing platform to sequence all samples with each lane of 
1X75nts, adapters were removed from raw read and trimmed depending on 
FastQC result. The coverage of sequencing was found to be very good for all 
samples with at least 24 million reads per sample and ranging up to 40 million 
reads per sample (Figure 4.8). 
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Figure 4.6:  RNA isolation and library preparation for RNAseq21 
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Figure 4.7:  Bio-informatics analysis of sequenced reads21 
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Trimmed reads from each sample were aligned with reference human genome 
using a tool called GSNAP (Genomic Short-read Nucleotide Alignment Program)22. 
Figure 4.9:  Alignment metrics for aligned samples 
Figure 4.8: The sequencing coverage for replicates of each samples 
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SAM files (Sequence Alignment Mapping) obtained from each alignment from each 
sample was used to get alignment metrics, which showed a good alignment of 
reads with our reference genome and similar alignment pattern among replicates 
for all samples, ranging from 50% to 90 % (Figure 4.9). Additionally, majority of 
aligned reads in our samples were uniquely aligned that means, these reads were 
aligned to only one position in reference giving a high confidence on expression 
analysis. After making sure our reads are aligned with reference genome well, 
each SAM file and reference human genome annotated file (gff file) is used to run 
HTseq23 to find out the read count and text file obtained for all the replicates were 
combined into a file and followed DESEQ2 work flow to measure differential gene 
expression24.  
PCA (principal component analysis) plot gives the characteristics of samples 
depending on nature of gene expression level. When we plotted PCA, we got a 
very clear separation of samples into three groups with replicates of each samples 
Figure 4.10:  PCA Plot for all samples 
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clustered together. This signifies that the gene expression pattern in each replicate 
for our samples are comparable or alternatively, there is variation between the 
samples but not between the replicates (Figure 4.10). 
We used MA plot to compare differential expression of genes in sample B (treated 
with antimiR-155, IDT) and C (treated with compound 27) as compared to control 
sample A (non-treated Cells only) as reference. In this plot fold change is 
calculated from read count value of genes as compared to reference sample gene 
count, and then it is transformed into log2 value, where any genes have fold 
change value equals to ‘1’, will have ‘0’ log2 value and these genes are not 
considered as differentially expressed genes. When log2 transformed values of 
fold change for all the genes are plotted against mean of normalized counts, all the 
genes with no differential expression will appear at the center (black dots in Figure 
Figure 4.11: MA plot to compare the differential expression of genes at two different 
treatment conditions with cells only as reference (padj ≤0.1) 
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4.11) whereas differentially expressed genes will appear around negative or 
positive axis depending on whether these are upregulated or down regulated (red 
dots in Figure 4.11).  First MA plot in Figure 4.11 (refA Vs B) gives the pattern of 
differentially expressed genes of antimiR-155 treated sample as compared to non-
treated cell reference whereas second plot (refA vs C) gives the pattern of 
differentially expressed genes of compound 27 treated cells as compared to non-
treated cell reference. If we look closely this result, it shows a very distinct 
characteristic as the antimiR-155 caused more fold change of differentially 
expressed genes that are upregulated whereas compound 27 caused more fold 
change of differentially expressed genes that are downregulated (Figure 4.11).  
Sample  Total number of differentially 
expressed genes 
Positive log2FC 
(Up-regulated) 
Negative Log2FC 
(Down regulated) 
RefA vs. B 1404 753 651 
RefA vs C 1935 1025 910 
  
Table 4.3: Number of Up- and Down-regulated genes in each condition (padj ≤0.05) 
It was found that compound 27 caused more genes to change expression as 
compared to antimiR-155 (Table 4.3). When we compared the list of differentially 
expressed genes in both conditions to each other, 12.8% of the genes are 
common. Among upregulated genes 9.5% of the genes are found to be common 
whereas in downregulated genes 8.5% of the genes are found to be common 
(Figure 4.12) 
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miR-155 target prediction and validated database 
To investigate if the genes changing expression upon treatment are miR-155 direct 
or downstream targets, we first compile the database of genes that are known or 
predicted to be miR-155 targets. We can then compare the RNAseq results with 
the database to validate the targeting as well as to identify new miR-155 targets 
and investigate the off targets of compound 27 and antimiR-155.  
Two in silico prediction software were used to predict miR-155 targets. 
“TargetScanHuman7.2” is a prediction software used to predict miRNAs targets by 
Figure 4.12: Comparison of number of differentially expressed genes in both 
conditions by similarity (‘refA vs B’ represents differentially expressed genes in 
antimiR-155 treated cells and ‘refA vs C’ represents differentially expressed genes 
in compound 27 treated cells, untreated cell sample (A) gene expression is used 
as reference)  
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the alignment of conserved 6, 7 or 8 nucleotides from the seed region of miRNA 
of interest with human 3' UTRs and their orthologs, as defined by UCSC whole-
genome alignments  as well as detected within open reading frames (ORFs)25,26. 
Similarly, “miRDB” is an online database for miRNA target prediction  and 
functional annotation. All the targets were predicted using bioinformatics tool called 
“MirTarget” and functionality of miRNAs were explored by computational method 
and literature mining27,28. Target genes for miR-155 (both -5p and -3p strands) 
were predicted using TargetScanHuman7.2 and 2,873 genes were identified at 
3’UTR region of human genome. Similarly, miRDB was used to predict miR-155 
target genes and 551 genes were identified at 3’ UTR region of human genome. 
We further analyzed by comparing these target genes obtained from two different 
Figure 4.13:  Comparison of miR-155 targets obtained from two different prediction 
tools (miR-155_Targetscan represents the targets obtained by using “TargetScanHuman7.2’ 
tool and miR-155_miRDB represents the targets obtained by using “miRDB”) 
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target prediction tools. Out of all predicted genes, 339 genes are common to both 
(Figure 4.13) 
Furthermore, one more database (miRTarBase7.0) that has information about 
updated experimentally validated miRNA target genes was used to find out the list 
of genes that are experimentally validated as miRNA targets.29 It includes the 
genes that are validated as miRNA target by one or more experimental methods 
like qPCR, western blot, reporter assay and/or microarray etc. By using this 
database, we prepared the list of genes that are validated experimentally as miR-
155 targets and 256 genes were found as validated miR-155 genes. When 
compared with common predicted genes from earlier two prediction tools, 45 
genes were found to be same in both list of genes (Figure 4.14). 
Figure 4.14: Comparison between common miRNA targets predicted and experimentally 
validated (miR-155_predicted represents the total common genes obtained by using two different 
prediction tools in Figure 4.13 and miR-155_validated represents experimentally validated targets 
obtained from miRTarBase7.0)  
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We will use union of all genes including common (predicted + validated) to 
compare with our experimentally upregulated genes. 
After generating the database, we selected differentially expressed genes with 
positive log2FC values (up-regulated) from each treatment condition and compare 
those with miR-155 target genes (predicted + validated) because all direct target 
genes of miR-155 should be upregulated with the repression of miR-155.  
A good fraction of genes in both treatment conditions were found to be similar to 
predicted miR-155 target genes, but majority of genes in each case were not in the 
Figure 4.15:  Comparison of upregulated genes for both samples with target genes A) 
comparison of anti-miR induced upregulated genes with miR-155 target genes B) comparison of 
compound 27 induced upregulated genes with miR-155 target genes C) common upregulated genes 
between anti-miR induced and compound 27 induced upregulated genes D) comparison between 
common upregulated genes with miR-155 target genes 
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list of predicted genes. This suggest either these genes are still valid targets but 
not been predicted or reported or they might be the secondary and downstream 
targets ofmiR-155 target genes. It is also possible that these gene changes are 
due to off-target effects that are irrelevant to miR-155 (Figure 4.15). 
To understand if there is any functional relationship among the changed genes 
and investigate what are the potential off targets, we carried out gene enrichment 
and pathway analysis of all the upregulated genes using Cytoscape-ClueGO 
software to cluster the functionally similar genes (Figure 4.16 and 4.17).30 
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Analyzing the genes that are upregulated upon antimir-155 treatment, we found 
the genes can be clustered to several functional groups including defense 
response, cell surface receptor signaling pathway, defense response to virus, 
response to organic substance, regulation of sequence specific DNA binding 
transcription factor, regulation of NF-kappaB (Figure 4.16). 
 
 
Figure 4.16: Pathway analysis for upregulated genes in anti-miR-155 treated samples A) 
Functionally grouped network with terms as nodes linked based on their kappa score level (≥0.3), 
where only the label of the most significant term per group is shown. The node size represents the 
term enrichment significance. Functionally related groups partially overlap (numbers 1-4 represent 
zoomed region) B) Overview chart with functional groups including specific terms for upregulated 
genes. 
B 
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Analyzing the genes that are upregulated upon compound 27 treatment, we found 
the genes can be clustered to several functional groups including sterol 
biosynthesis, cytoplasmic vesicle, cytoplasmic part, endomembrane system 
organization, single-organism biosynthesis process (Figure 4.17). 
By comparing functional cluster of upregulated genes, we found low similarity 
between these two treatment conditions (Figure 4.16 and 4.17) and each of these 
also have low overlaps with the predicted and validated miR-155 targets (Figure 
4.15). All of these results suggest that both antimir-155 and compound 27 have 
significant and distinct off targets and effects. We are still in the process of further 
analyzing the data using additional bioinformatics tools. 
B 
Figure 4.17: Pathway analysis for upregulated genes in compound 27 treated samples A) 
Functionally grouped network with terms as nodes linked based on their kappa score level (≥0.3), where 
only the label of the most significant term per group is shown. The node size represents the term 
enrichment significance. Functionally related groups partially overlap B) Overview chart with functional 
groups including specific terms for upregulated genes. 
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4.3 Conclusion  
We discovered compound 27, to be a new pre-miR-155 binder through a 
peptidomimetics library screening, which also show in-vitro and cellular activity. 
RNAseq analysis from samples of cells treated with compound 27 and antimir-155 
showed that although a certain number of differentially expressed genes in both 
treatment conditions matched predicted miR-155 target genes, there are a large 
fraction of differentially expressed genes in both conditions showed no direct 
connection to miR-155 targets. Further analysis of these genes should give 
information regarding the off-target effects of both molecules.  
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4.4 Methods 
Alpha-P32-UTP labelling of pre-miR-155  
The sequence of pre-miR-155 was obtained from miRBase 
(http://www.mirbase.org/). The DNA template used for making pre-miR-155 RNA 
was generated by PCR primer extension. Briefly, forward primer:  
5'-
GAAATTAATACGACTCACTATAGGCTGTTAATGCTAATCGTGATAGGGGTTT
TTGCCTCCAACTG-3’ 
and reverse primer: 
5'-CTGTTAATGCTAATATGTAGGAGTCAGTTGGAGGCAAAAACCCCTA-3’ 
0.8 μM of each were subjected to primer extension using Taq polymerase 
(Ambion) per the manufacture’s protocol. The extended dsDNA was purified with 
NucleoSpin gel and PCR clean-up kit (Macherey-Nagel). The hybrid DNA template 
with T7 promoter was used for in vitro transcription using T7 polymerase following 
manufacturer’s instructions (New England Biolabs). The reaction mixture was 
treated with DNase to digest the template DNA and then extracted with 
phenol/chloroform/isoamyl alcohol (25:24:1) (pH 6.7). The RNA was finally 
precipitated by ethanol and resuspended in water for storage at -20 °C. Right 
before use, the RNA was allowed to refold as follows: RNA was heated to 94 oC 
for 2 min and then cooled to 4o C at a rate of 1o C/s.   
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Preparation of fluorophore labeled pre-miR-155 
5'-GMPS primed pre-miR-155 were first prepared by in vitro transcription as 
described above except that 5’-GMPS(Biolog):GTP:ATP:CTP:UTP (8:1:1:1:1 mM) 
was used.23 The RNA was purified by phenol/chloroform extraction and ethanol 
precipitation. ATTO 488 was then conjugated onto RNA via the 5’ thiol group 
following a reported method.24 5'-GMPS primed pre-miR-155 (10 µg) was 
dissolved in PBS (1 mL, pH 8.3), followed by the addition of ATTO 488-
Iodoacetamide for pre-miR-155 and ATTO 590-Iodoacetamide for pre-miR-21 (1.3 
equiv) (ATTO-TEC). The reaction was kept in dark at 37 °C for 2 h. The labeled 
RNA was purified by phenol/chloroform extraction and ethanol precipitation. 
Cell culture   
HEK293T and MCF-7 cells were cultured in DMEM medium (Gibco) without 
antibiotics, supplemented with 10% FBS and 2 mM GlutaMAX (Life Technologies) 
at 37 °C in a humidified atmosphere containing 5% CO2.  
Dicer cleavage inhibition assay 
32P-labeled pre-miR-155 was prepared as described earlier. A 10 µL of the reaction 
mixture was made by incubating 32P-labeled pre-miR-155 (1 µL, ~20 ng) with Dicer 
enzyme (Gen-Lantis) (1 µL) and various concentrations of 24 in buffer (HEPES 24 
mM, NaCl 200 mM, EDTA 0.04 mM, MgCl2 2.5 mM, ATP 1 mM, pH 7.5) at 37 °C 
for 2.5 h. The reaction was stopped by boiling with equal volume of Gel Loading 
Buffer II (ThermoFisher Scientific) for 5 min. The non-cleaved pre-miR-155 and the 
processed miR-155 were resolved by 18% denaturing polyacrylamide gel. The gel 
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was imaged with phosphor imager and analyzed by quantity one software (Bio-
rad). 
MiR-155 inhibition in cell 
MCF-7 cell was used for studying the activity of 24 in inhibiting endogenous miR-
155 in cell. The cells were plated in 24-well plates (500 µL of medium per well) and 
grown overnight to   ̴60% confluency. The cells were then treated with 24 (30 µM), 
DMSO (0.2% v/v) or anti-miR-155 (30 nM, transfected as described above) 
(Integrated DNA Technologies). The cell cultural medium was replaced with fresh 
one containing the corresponding small molecule every 24 h. The cells were 
harvested after 4-day incubation for the following RT-qPCR, Western blotting, and 
flow cytometry analysis. 
RNA extraction (RNAseq sample preparation) 
Total RNA was extracted using miRNeasy Mini Kit (Qiagen) per the manufacturer’s 
protocol for both RT-qPCR and RNAseq. MiRNA reverse transcription reactions 
were completed using a Taqman MicroRNA RT Kit (Applied Biosystems) per the 
manufacturer’s protocol analyzed by nanodrop and sent for sequencing. 
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